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The Governor’s Commission on Alcohol and Drug Abuse Prevention, Intervention and Treatment (hereafter 
referred to as “the Commission”) was established by the state legislature in 2000, with its membership and duties 
articulated in RSA 12-J:4. These duties include the following: 
 
- Developing and revising as necessary a statewide plan for the effective prevention of alcohol and drug 
abuse, particularly among youth; and a comprehensive system of intervention and treatment for individuals 
and families affected by alcohol and drug abuse; 
- In partnership with the NH Department of Health and Human Services, overseeing disbursement of the 
Alcohol Abuse Prevention and Treatment Fund; 
- Promoting collaboration between and among state government agencies and communities to foster the 
development of effective community-based alcohol and drug abuse prevention and treatment programs; 
- Promoting the development of treatment services to meet the needs of citizens addicted to alcohol or other 
drugs; and 
- Identifying unmet needs and identifying the resources required to reduce the incidence of alcohol and drug 
abuse in NH and to make recommendations to the Governor regarding legislation and funding to address 
such needs. 
 
In its ongoing surveillance of substance use issues in the state, the Commission has noted the epidemic of 
prescription drug abuse as a public health crisis in New Hampshire, with an alarming increase in prescription drug 
related deaths now outpacing traffic fatalities in the state. Crimes related to prescription drug abuse are also on the 
rise, including theft and illegal distribution. Such abuse has both economic and social costs that are a burden to 
local communities and the state as a whole. 
 
Over the past year the Commission has led an effort to respond to the crisis through the development of this 
comprehensive strategy document. This effort dovetails with similar work on the federal level, which was 
articulated by the Office of National Drug Control Policy (ONDCP) in its report, Epidemic: Responding to 
America’s Prescription Drug Abuse Crisis. Gil Kerlikowske, Director of ONDCP, joined the Commission in 
October to review and comment on recommendations proposed in the New Hampshire Call to Action, along with 
stakeholders from law enforcement, health care, education, local and state government and business.  
 
The Commission thanks the many stakeholders – both local and national – who participated in focus groups, 
convenings, and other efforts to gather data and develop this strategy document. Particular thanks goes to the New 
Hampshire Center for Excellence in Substance Abuse Prevention and Treatment, a co-funded initiative of the 
New Hampshire Bureau of Drug and Alcohol Services, the Commission and the New Hampshire Charitable 
Foundation, for their leadership in facilitating the strategy development process and producing this document for 
dissemination to the public.  
 
The Commission looks forward to working with these stakeholders, the Legislature and the Governor’s Office to 
ensure effective implementation of the recommendations contained herein. We are fortunate as a state to have 
seen local communities and others already begin implementation of a number of initiatives and policy efforts that 
we recommend here, but there remains much work to do to ensure we can turn the tide of this epidemic and 
reduce the negative economic and social impact prescription drug misuse and abuse has on our state. 
 




     
 Timothy R. Rourke, Chairman  Joseph P. Harding, Executive Director 








































































New Hampshire’s awareness of and response to the threat of prescription drug abuse began 
as early as 2004, when prescription drug-related deaths were on the rise and state agencies 
began to make policy changes in response to the emerging threat.  In spite of these important 
strides, increased marketing and accessibility of prescription drugs, low perceptions of the 
risks associated with the misuse and abuse of prescription drugs, and a rise in prescription 
drug fraud have overtaken these early and isolated efforts. 
 
According to the most recent data available, the number of deaths in New Hampshire 
attributable to drug-related deaths – the majority of which are prescription drug-related – has 
outnumbered traffic related fatalities in four out of the last five years, and the New 
Hampshire rate of young adults reporting nonmedical use of pain relievers in the past year is 
second highest among the states and territories.   
 
These alarming statistics prompted the Governor’s Commission on Alcohol and Drug Abuse 
Prevention, Intervention and Treatment to lead a year-long effort to mine federal, national, 
state and local recommendations  in order to develop a comprehensive action plan to respond 
to the threat in a more timely and comprehensive manner.   
 
The assessment and planning work of the Commission and its task forces during 2011 led to 
key recommendations, including the following: 
 
- Increase professional development and training within and across multiple sectors 
- Improve  prescribing, dispensing, storage, disposal and enforcement practices and 
policies 
- Increase surveillance and monitoring at the individual (patient) and system level 
(population data) 
- Increase public education and awareness (including patient education) 
 
The Commission has engaged state agencies and regulatory authorities to support community 
stakeholders within health, safety, education, business and government sectors to consider 
and carry out the recommendations within this Call to Action.  In so doing, the Commission 
seeks to reduce drug-related deaths and nonmedical use of pain relievers by 15% over the 
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This document is endorsed by the New Hampshire Governor's Commission on Alcohol and Drug Abuse 
Prevention, Intervention and Treatment whose mission by statutory obligation and professional 
commitment is to significantly reduce alcohol and drug problems and their behavioral, health and social 
consequences for the citizens of New Hampshire by advising the Governor regarding policy, funding and 
the delivery of effective, efficient, coordinated alcohol and drug abuse prevention, intervention, treatment, 
and recovery services. 
 
Through the development, endorsement, dissemination and implementation of the enclosed plan to 
prevent and reduce prescription drug misuse and abuse, we serve our collective mission and the well-
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The misuse and abuse of prescription drugs has become a leading cause of harm among New 
Hampshire adults, resulting in more deaths each year than those caused by car crashes.  The rise of 
prescription drug abuse is rooted in multiple contributing factors, including increasing availability 
and accessibility, a misperception of low risk of harm relative to other illicitly obtained drugs, 
direct to consumer marketing of prescription medications, and a lack of education about the 
potential risks of misusing or abusing prescription drugs, including the risk of addiction and death. 
 
Prescription medications include a wide range of abusable drugs, including opioids (for pain), 
central nervous system depressants (for anxiety and sleep disorders), and stimulants (for attention 
deficit disorder and narcolepsy).  
 
 
CLASSES OF COMMONLY ABUSED PRESCRIPTION MEDICATIONS 
 



























































The most potent and addictive medications being prescribed are opioid pain relievers such as 
oxycodone.  Opioids play a critical role in the quality of life for those with acute and/or chronic 
pain; however, it is imperative that prescribers and patients alike are aware of their potential harm. 
 
According to the National Institute on Drug Abuse (NIDA) at the National Institutes of Health, 




 ADDICTION  Prescription opioids act on the same receptors as heroin and therefore can be 
 highly addictive. People who abuse them sometimes alter the route of administration (e.g., 
 snorting or injecting vs. taking orally) to intensify the effect; some even report moving 
 from prescription opioids to heroin.  
 
 OVERDOSE Opioid abuse, alone or in combination with alcohol or other drugs, can depress 
 respiration and lead to death. Overdose is a major concern, as the number of fatal 
 poisonings involving prescription pain relievers has more than tripled since 1999.  
 
 HEIGHTENED HIV RISK Injecting opioids increases the risk of HIV and other infectious 
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NIDA also has articulated the risks associated with the misuse or abuse of other prescription 
central nervous system (CNS) depressants used to treat anxiety and sleep disorders: 
 
 ADDICTION & DANGEROUS WITHDRAWAL SYMPTOMS CNS depressants are addictive 
 and, in chronic users or abusers, discontinuing them without a physician's guidance can 
 bring about severe withdrawal symptoms, including life-threatening seizures.  
 
 OVERDOSE High doses of CNS depressants can cause severe respiratory depression. This 
 risk increases when CNS depressants are combined with other medications or alcohol. 
 
Stimulants used to treat attention deficit disorder and narcolepsy also pose risks including 
addiction, seizures, psychosis and cardiovascular complications.  
 
Although swift and comprehensive action is necessary to prevent and reduce prescription drug 
misuse and abuse, it is imperative that critical pain treatment and medication management remain 
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National data show the quantity of medications made available through valid prescriptions steadily 
increasing since the 1990’s, increasing overall accessibility and the potential for misuse and abuse.  
According to the White House Office of National Drug Control Policy, the milligram-per-person 
use of prescription opioids per year in the U.S. increased from 74 milligrams to 369 milligrams 
between 1997 and 2007, an increase of 399% in ten years,
2
 and pharmacies dispensed 83 million 
more opioid prescriptions in 2009 compared to 2000, an increase of 48%.
3
  According to a 2008 
study by the International Narcotics Control Board, the United States consumes 99 percent of the 









































Source: White House Office of 
National Drug Control Policy 
The annual milligram- 
per-person use of prescription 
opioids in the U.S. increased 
from 1997 to 2007. 
A Nation’s Epidemic 
Source: CDC/NCHS, National Health and Nutrition Examination Survey 
 
Note: Age adjusted by direct method to the year 2000 projected U.S. population 
 
Sources: National Vital Statistics System, 1999-
2008; Automation of Reports and Consolidated 
Orders System (ARCOS) of the Drug Enforcement 
Administration (DEA), 1999-2010; Treatment 
Episode Data Set, 1999-2009 
 
Rate of prescription painkiller sales, death and 




Increases in availability and 
accessibility have also led to 
drug-seeking crimes, referred to 
as “diversion”, which include but 
are not limited to forged 
prescriptions, theft, and doctor 
shopping – the practice of 
contacting multiple doctors for 
the purpose of acquiring 
prescription medications for 
abuse or illicit resale.  As 
prescribing has increased, there 
have been similar increases in the 
prevalence of fatal prescription 
overdoses and in the prevalence 
of treatment admissions for 
prescription painkiller abuse and 
dependence.   
Trends in the percentage of persons using  
prescription drugs (1999-2008) 
* Significant linear trend from 1999-2000 through 2007-2008 

















In response to the growing problem nationally, the Executive Office of the 
President of the United States issued a briefing in April 2011 titled, Epidemic: 
Responding to America’s Prescription Drug Abuse Crisis, which encourages 
states to develop an effective response to “the Nation’s fastest-growing drug 
problem”.  The briefing characterized prescription drug misuse as an epidemic 
based on the following indicators: 
 
One in three people aged 12 and over who used  
drugs for the first time in 2009 began with the  
use of a prescription drug for nonmedical purposes;
5
 
In 2008-2009, over 70% of those who abused pain  
relievers reported getting them from friends or  
relatives while 5% obtained them from a drug  
dealer or the internet;
6
 
Prescription drugs are second only to marijuana  
as the most prevalent drug of abuse;
7
 
Illicit drug abuse, particularly prescription drug abuse, among the military increased 
from 5% to 12% between 2005 and 2008;
8
 




Opiate overdoses are increasing due to abuse of prescription pain relievers;
10
 




Source Where Pain Relievers Were Obtained for Most Recent  





















Source: Epidemic: Responding to 
America’s Prescription Drug Abuse Crisis 
Opiates represent 
¾ of all 
prescription drugs 
being abused. 
























The most telling indicator of New Hampshire epidemic is the steady increase in total drug-related 
deaths since 2000, with the majority of the increase attributable to prescription drug overdose.  
The number of drug-related overdose deaths in the state increased substantially between 2002 and 
2010, more than doubling from 80 deaths to 174 over the eight year period.  Prescription opioids 
are the most prevalent drug of abuse leading to death.
13 
 
With such a devastating toll already evident in the state, the Commission 
initiated a community- and state-level assessment of the scope and severity of 
the threat, of current efforts to address the negative impacts affecting many 
aspects of public safety and health, and of opportunities for community- and 
state-level response and action. This assessment process, undertaken by the 
Commission and its prevention task force, is described below and is the 















In addition to information derived 
through stakeholder engagement, 
quantitative data accessed by the 
Commission includes state-level data 
from the Youth Risk Behavior Survey, 
the National Survey on Drug Use and 
Health, the Client Event Data Set of state-
funded treatment providers, Mental 
Health Intake Screening data of state 
corrections populations, and cause of 
death statistics from the New Hampshire 
Medical Examiner’s Office. A summary 
of key findings from these data sources is 
provided as context for the Commission’s 
Call to Action. Source: 2008-2009 NSDUH 14 
 
A community survey of over 
110 stakeholders and 
community leaders, 
including representatives 
from the law enforcement, 
education, social service, 
health & medical sectors  
A survey of 
8 state agencies 
represented on the 
Commission  
16 key informant 
interviews with licensing 
boards and state agency leaders  
A Strategy Summit held October 3, 2011 
engaging over 160 state & community 
stakeholders & lawmakers in the 
review and prioritization of strategies 
derived from federal, national, state & 
local sources  
Past year nonmedical use of pain  
relievers by age groups in NH 
2011 – Governor’s Commission on Alcohol and Drug Abuse 
 MAR APR MAY   JUN   JUL   AUG   SEP OCT 
New Hampshire’s Epidemic 





















According to the 2008-2009 National Survey on Drug Use and Health, New Hampshire’s young 
adults are abusing pain medication at a significantly higher rate than young adults nationwide 
(NH =16.78% vs. US=11.94%); New Hampshire’s rate of nonmedical use of pain relievers by 18 
to 25 year olds is the second highest among the states and territories. 
Between 2008 and 2010, the percentage of individuals entering state-funded substance abuse 
treatment  for oxycodone increased by over 60%, from 11.6% of patients in 2008 to 18.7% of 
patients in 2010, while admissions for alcohol, cocaine, marijuana, and heroin either decreased or 
stayed the same.  In 2010, oxycodone also became the second most prevalent drug of abuse after 




According to the New Hampshire 
Medical Examiner’s Office the number 
of New Hampshire deaths resulting 
from oxycodone has more than tripled 
since 2000. The total number of drug-
related deaths rose to 174 in 2010.  
Almost 20% of these deaths (34) were 








Source: Dr. Thomas Andrew, NH Medical Examiner’s Office 
In 2010 methadone and oxycodone became the first and second leading agents in the cause of 
drug-related deaths in New Hampshire.
17
 
Approximately one in five (20.4%) New Hampshire high school students reported having taken a 
prescription drug without a doctor’s prescription at least once in their lifetime, while one in ten 
(10.4%) reported having taken a prescription drug without a doctor’s prescription at least once in 
the past 30 days.
18
    




 graders found that 40% believed using prescription 
drugs was safer than using illegal drugs, 29% thought that pain relievers were not addictive, and 
62% of teens who reported abusing prescription pain relievers said they do so because they are 
easily accessible through parents’ medicine cabinets.
19
 
In 2010 sixteen percent of substance abusing adults entering state correctional facilities reported 
prescription drugs as their drug of first preference.
20
 
From April of 2010 to April of 2011, the Drug Diversion Unit of the NH Department of Safety 
initiated 32 investigations resulting in one search warrant, four consent searches, and 50 arrests 








Number of Drug Related Deaths in NH 







In this Call to Action, the Commission supports the federal recommendation
22
 that the following 
long-term impacts be achieved within five years: 
 
 A reduction in the percentage of individuals 12 and older who report  
 non-medical use of pain relievers in the past year by 15% 
  
 A reduction in the number of drug-related overdose deaths by 15% 
 
To realize these goals, this Call to Action frames the issue in two parts:  
 
 Part I: Recommendations for Action  
   Recommended strategies by key stakeholder domains 
 
 Part II: Commitments to Action  
   Specific commitments to action by state level agencies and stakeholder groups 
 
This two-tiered plan will ensure a wide range of opportunities for and commitments to actionable 
strategies that comprise the state’s comprehensive response to the growing epidemic of 
prescription drug abuse.  Strategies included in this document were prioritized as highly or 
moderately feasible with a high to moderate impact by stakeholders at the 2011 Prescription Drug 
Abuse Prevention Strategy Summit and/or in review by the task forces of the Governor’s 

























Recommended strategies in the first 
section of this document are organized 
by the following domains:   
PROFESSIONAL DEVELOPMENT & TRAINING 
PUBLIC EDUCATION & AWARENESS 
PRESCRIBING & DISPENSING 
STORAGE & DISPOSAL 









































Recommended strategies within this plan have broad implications from the practitioner at the 
community level to legislative policy at the government level and across key state and community 
sectors. 
 
This cross-section of stakeholders and strategy domains is designed to harness the resources and 
opportunities that exist within the state and local communities to effect positive change in service 
to the state’s goal of preventing and reducing prescription drug abuse.  
  
Recommendations and opportunities for action are presented by key stakeholder sectors that exist 
within communities and state-level leadership.  For each key sector, recommendations are 












































 Local Law Enforcement  
 Emergency Medical Technicians & First Responders 
 
 Health Educators 
 Addiction Treatment 
 
HEALTH & MEDICAL 
SAFETY & LAW ENFORCEMENT 
 Public & Private Schools 
 Campus Health Services 
 
 Business Owners & Operators 
 Human Resource Departments  
EDUCATION 
 Drug Diversion Investigators 
 Police Standards & Training  
 
 
 Federal Government 
 State Lawmakers 
 
 
 County Officials 
 Local Governing Boards 
 State Agencies & Commissions 
GOVERNMENT 
BUSINESS 
 Senior Management 
 Health Educators 
 Safety Compliance Officers 
 
 Emergency Care 
 Behavioral Health 
 Surgeons 
 Injury Prevention 
 
 Primary Care 
 Institutional Care 
 Pain Clinics 
 Suicide Prevention 
 
 School Nurses 
 Campus Police 
 
 Student Assistance Counselors 
 College Counseling Departments 
 Staff & Administration 
 Guidance Counselors & Social Workers 
 
 Employee Assistance Programs 
 Risk Management  
 











































































































HEALTH & MEDICAL 















































1:1 Increase training availability and access for the health care workforce 
1:2 
Increase opportunities for cross-training between prescribers, dispensers, health educators, 
and law enforcement specializing in drug diversion 
1:3 
Increase training opportunities for addiction prevention and treatment professionals in 
evidence-based treatment and after-care relative to prescription drug abuse 
1:4 Increase educational requirements for those seeking to enter the health and medical field 
1:5 
Increase professional collaboration between providers of primary care, behavioral health, 






Provide education to all patients and clients regarding the risks and warning signs of 
prescription drug abuse and misuse, proper storage and disposal of medications, and 






Prescribers should check a patient’s prescription history before prescribing controlled 
substances 
1:8 
Prescribers should screen for substance abuse as part of standard clinical examination and 
assessment 
1:9 
Prescribers should provide medication guides and counseling to patients relative to 
potential harm, including addiction 
1:10 
Prescribers should closely evaluate, monitor and even test patients for prescription drug 






Patient education should include information about proper storage and disposal of unused 
medications 
1:12 
Health and medical staff and facilities should promote and support local “Take-Back” 
events to encourage safe and regular disposal of unused medications 
1:13 Pharmacies may consider serving as medication disposal sites 
 
Health & Medical Recommendations Overview 
PUBLIC EDUCATION & AWARENESS 
PRESCRIBING & DISPENSING 
STORAGE & DISPOSAL 







































Prescription drug monitoring should be instituted by means of a centralized database 
accessible to prescribers and dispensers 
1:15 
Prescribers and prescribing facilities may consider patient contracts and other protocols to 
monitor and detect prescription drug diversion and/or abuse 
1:16 
Dispensers should take increased precautions to protect stock and prevent unlawful access 
to prescription drugs 
1:17 
Licensing boards and authorities should monitor, investigate and enforce policies and 
encourage enhanced protocols to deter abuse and diversion 
1:18 
Referral to appropriate intervention or treatment should be provided if indications of abuse 



























SURVEILLANCE & MONITORING 




































The health and medical sector within the state plays a unique and critical role in efforts to address 
the threat of prescription drug misuse and abuse in that they are one source of the medications that 
hold the potential for abuse. Prescribing physicians, surgeons, emergency room staff and other 
medical, dental and mental health professionals are in a difficult, front-line position of having a 
responsibility to treat chronic and acute conditions requiring pain and symptom relief within a 
changing landscape wherein patients may be seeking the drugs specifically for abuse or diversion 
for illicit activity.   
 
Health and medical professionals also have unique opportunities to talk with patients about the 
danger of prescription drug abuse and addiction, to discuss ways to safeguard medications to 
prevent access by others, and to identify patients who may be abusing medications to refer them to 
treatment. 
 
The Call to Action in the health and medical sector seeks to engage the broadest spectrum of 
professionals and practitioners in strategies to prevent and reduce prescription drug misuse and 
abuse in New Hampshire. The health and medical sector includes all members of the health care 
workforce and their employers, including but not limited to those indicated below. 
 
PRESCRIBERS DISPENSERS HEALTH EDUCATORS ADDICTION TREATMENT 
Primary care practitioners, 
emergency room staff, 
surgeons, dentists & oral 
surgeons, pain care 
professionals, psychiatrists, 
nurse practitioners, and other 
medical professionals licensed 
to prescribe
Pharmacists, pain clinics, 
institutions such as nursing 
homes & correctional facilities 
licensed to dispense 
prescribed medication 
Health educators in schools, 
communities, housing 
authorities, social service 
organizations, and 
institutional settings; injury 
prevention, suicide 
prevention, and poison control 
professionals 
Licensed alcohol & drug 
counselors, therapeutic 
counselors, social workers, 
and recovery support workers 
 
During this plan’s development it was noted that individuals abusing pain medication may resort 
to extreme measures to gain access to medications that further complicate and challenge the 
practice of prescribing medication.  For example, it was reported that there have been cases of 
drug seekers presenting in New Hampshire emergency rooms for dental pain that emergency room  
Health & Medical Recommendations 
 





























PROFESSIONAL DEVELOPMENT & TRAINING 
staff may not be able to adequately assess, thereby potentially increasing the likelihood pain 
medication will be prescribed.  Drug seekers may also leave dental or other medical problems 
untreated in order to maintain the condition that requires pain medication or the appearance of 
requiring pain medication. These and other conditions and situations are exploited by drug seekers 
to thwart a prescriber’s reliance on objective means to determine the cause and severity of pain.  
 
Interviews conducted in the development of this plan also revealed that many individuals who 
become drug seekers fall into their abuse and dependence as a result of a valid health or medical 
condition requiring pain or other symptom relief and that the health and medical field must give 
equal attention to treating symptoms and conditions as to preventing complications from such 
treatment, including the potential of abuse and addiction.   
 
New Hampshire’s health and medical field has already taken the lead in revising pain treatment 
guidelines and improving patient monitoring to deter prescription drug abuse. To assist 
stakeholders in responding to the Call to Action, resources and examples in support of 
recommended strategies are provided. These and other local efforts that have shown success are 
highlighted along with state and national resources, including websites, guidelines, and materials. 





1:1 Increase training availability and access for the health care workforce 
 
All health care professionals licensed to prescribe medication should receive comprehensive 
training in the following areas to increase awareness of prescription drug misuse and abuse, to 
implement effective prevention approaches, and to intervene early if a problem arises.  
 
PRESCRIBERS DISPENSERS HEALTH EDUCATORS ADDICTION TREATMENT 
Evaluation & treatment of pain 
Effective pain management 
Reviewing patient history 
Patient monitoring & contracts 
Abuse prevention  
Physiology of addiction 
Problem identification & referral 
Screening for abuse & 
dependence  
Warning signs of abuse & 
dependence 
Internal drug diversion 
Monitoring of customer 
prescription drug fills & 
patterns  
External drug diversion 
Safe storage & disposal of 
medication  
Warning signs of abuse & 
dependence 
Abuse prevention  
Problem identification & 
referral 
Evidence-based treatment for 
opioid addiction   
Medication-assisted recovery 




Recommended training topics include but are 
not limited to those indicated above. 


























The draft “Blueprint for Prescriber Continuing Education Program” is available at: 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Federal legislation has been submitted recently to require a minimum training course for anyone 
licensed to prescribed medication. The legislation, the Ryan Creedon Act of 2011, H.R. 2119, was 
filed on June 3, 2011, by leaders of the Congressional Caucus on Prescription Drug Abuse and 
named after a constituent of U.S. Representative Mary Bono Mack who died from a prescription 
drug overdose.   
 
This legislation seeks to amend the Controlled Substances Act to require practitioners to:  
 
Obtain particular training or special certification, approved by the Attorney 
General, on addiction to and abuse of controlled substances and appropriate and 





Additionally, in November 2011, the U.S. Food and Drug Administration (FDA) requested public 
comment on new risk evaluation and mitigation strategies (REMS) to be required of the sponsors 
of long-acting and extended-release (LA/ER) opioid drugs.  The central component of the Opioid 
REMS is an education program for prescribers (e.g., physicians, nurse practitioners, physician 
assistants) so that LA/ER opioid drugs can be prescribed and used safely. The FDA announced 
that it expects drug sponsors to provide prescriber training conducted by accredited continuing 







This FDA requirement and resulting resources will play an important role in the accessibility of 







Increase opportunities for cross-training between prescribers, dispensers, 
health educators, and law enforcement specializing in drug diversion 
 
Cross-training opportunities that bring diverse disciplines together are advantageous to creating 
opportunities for collaborative and coordinated strategies to prevent prescription drug abuse and 
diversion.  For example, the New Hampshire Board of Pharmacy is encouraging collaborative 
trainings and information-sharing between prescribers and dispensers to share ideas for more 
coordinated abuse prevention. Cross-training opportunities may also exist between medical and 
pharmacy schools such as Dartmouth College and the Massachusetts College of Pharmacy in 
Manchester, New Hampshire. 
 
Additionally, in response to the growing prescription drug abuse problem in New Hampshire, the 
Department of Safety’s Drug Diversion Unit was established to investigate various crimes 
involving diversion of pharmaceutical drugs, including prescription fraud, doctor shopping, illegal 
prescribing by medical professionals and employee thefts at pharmacies.  In addition to this 
charge, the Drug Diversion Unit commits half of its staff time to provide free trainings both within 



































PROFESSIONAL DEVELOPMENT & TRAINING 
PROFESSIONAL DEVELOPMENT & TRAINING 






Increase training opportunities for addiction prevention and treatment 
professionals in evidence-based practices and after-care relative to 
prescription drug abuse 
 
There are several state and regional training centers to support professionals in addiction services 
to expand their knowledge of effective treatment and after-care for individuals addicted to opioids.   
The New Hampshire Training Institute on Addictive Disorders offers low-cost trainings open to 
the public, including trainings on the physiology of addiction, evidence-based treatment, recovery 
support services, and drug trends.  Additionally, the New England School of Addiction Studies 
and the Addiction Technology Transfer Center at Brown University are regional resources 
offering professional development and training in addiction, including problem identification and 







Increase educational requirements for those seeking to enter the health and 
medical field 
 
Although several colleges and universities in New Hampshire have or are considering specialized 
coursework in addiction, it is recommended that all post-secondary educational programs 
preparing students for work in the health and medical professions expand or adjust required 
coursework to include training on addiction, prescription drug abuse, and related topics to increase 
the general knowledge of the health care workforce regardless of specialization.  Similarly, it is 
recommended that medical schools require adequate training of medical students in pain 







Increase professional collaboration between providers of primary care, 
behavioral health, addiction treatment, substance abuse prevention, and 
alternative therapies 
 
During the Prescription Drug Abuse Strategy Summit held October 3, 2011, primary care and 
addiction treatment professionals recognized the communication barriers between the fields of 
practice that may be hampering referrals to treatment or recovery support services. Interagency 
coordination is recommended to facilitate bi-directional referrals and care coordination between 
primary care and addiction treatment and recovery.  Substance abuse prevention services may also 




































Provide education to all patients and clients regarding the risks and warning 
signs of prescription drug abuse, proper storage and disposal of medications, 
and identify resources available for addiction treatment or recovery services 
 
Patient education is one means of growing public awareness of the potential harm of prescription 
drugs, particularly the risk of abuse and dependence and the potential harm of over-medicating. 
Providing meaningful information on risks and warning signs of dependence, the interactions of 
alcohol and other drugs with prescription medications, and when to contact a prescriber to discuss 
concerns is a vital component of patient education. Because prescription drug misuse is a growing 
epidemic, health and medical professionals should consider disseminating educational materials to 
patients in an overt way, such as through a direct conversation and proffered materials, in addition 
to passive means such as posters and brochures available in a waiting room.  
 
Statistics show that most prescription drugs being abused are accessed through friends or family 
members.  Patient education should include information on the importance of storing medication 
in places that are not visible or accessible to others.  In addition, education should include proper 
means to dispose of unused medications such as local Take-Back events or secure drop boxes.  
 
In addition to information on risk of abuse and safe storage and disposal, patients should receive 
information on accessing treatment and recovery services if a problem is identified.  Implementing 
this strategy may also encourage partnerships between primary care or other health settings and 






Prescribers should check a patient’s prescription history before prescribing 
controlled substances 
Prescribers should use available means to check a patient’s history for signs of abuse before 
prescribing controlled drugs.  Although a centralized database such as a prescription drug 
monitoring program discussed in other sections of this plan is one means, prescribers may use 
electronic health records to look for indications of abuse or drug-seeking behavior.  In the absence 
of an electronic means, doctors may contact 
pharmacists directly to confer on individual cases. 
Once a centralized database is established for 
physicians to utilize in support of this 
recommendation, dispensers must report the 
dispensing of prescription medication in a way that 
makes this information readily available in real-time 
for effective use by prescribers.  By reviewing a 
patient’s history in real-time, opportunities for abuse 
or diversion will be reduced.  
PRESCRIBING & DISPENSING 
PUBLIC EDUCATION & AWARENESS 




































Prescribers should screen for substance abuse as part of standard clinical 
examination and assessment 
 
Given that approximately one in ten adults (9.58%) in New 
Hampshire meet the criteria for abuse or dependence on alcohol or 
other drugs,
28
 prescribing practices should include brief screenings 
for substance abuse or a substance abuse history, particularly when 
a prescription for opioids may be considered.  A brief screen 
provides an opportunity for a discussion of a patient’s history of 
substance use and consideration of the potential impact a 
prescription medication may have on a patient’s use or sobriety, 
allowing for a substance use disorder to be considered in 






Prescribers should provide medication guides and counseling to patients 
relative to potential harm, including addiction 
 
Patient education should be provided whenever an opioid or any abusable medication is 
prescribed, detailing not only the risk of harm of taking the prescription in a way other than 
prescribed but also encouraging safe storage and disposal of unused medications to minimize 
possible harm to others.  In particular, access to prescription drugs should be minimized to protect 
people, including youth, who may be seeking a recreational high and to protect against accidental 








Prescribers should closely evaluate, monitor and even test patients for 
prescription drug misuse and abuse 
 
In light of the prevalence of substance use disorders and the growing epidemic of prescription 
drug misuse and abuse, it is recommended that prescribers consider a means to effectively monitor 
patients who have been prescribed abusable drugs, particularly opioid pain relievers.  One method 
that some New Hampshire clinics have adopted is patient contracts, discussed in Recommendation 
1:15 of this section.  Contracts allow for ongoing testing and monitoring of patients to ensure 
opioids are taken as prescribed.  See also Appendix C for a sample patient contract currently being 
used in New Hampshire to monitor patients who may be at risk for misuse or abuse.
PRESCRIBING & DISPENSING 
PRESCRIBING & DISPENSING 
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Patient education should include information about proper  
storage and disposal of unused medications 
 
As mentioned in the prescriber recommendations above, patient education 
should be provided whenever an opioid or any abusable medication is 
prescribed, encouraging safe storage and disposal of unused medications 
to minimize possible harm to others.  In particular, access to prescription 
drugs should be minimized to protect young people who may be seeking a recreational high and 






Health and medical staff and facilities should promote and support local 
“Take-Back” events to encourage safe and regular disposal of unused 
medications 
 
The success of state and local Take-Back events hosted by partnerships between law enforcement 
agencies, community anti-drug coalitions, pharmacies, and other organizations have underscored 
the abundance of unused medications in homes that may be accessed by drug seekers or that may 
pose a risk as a result of accidental or inappropriate use or abuse.  Support for these initiatives by 
health and medical professionals will help send a consistent message to individuals and 


















DEA’s Third National Prescription Drug Take-Back Event Collects 188.5 Tons 
 
     NOV 03 - (WASHINGTON, D.C.) – Americans participating in the U.S. Drug Enforcement Administration’s (DEA’s) 
third National Prescription Drug Take-Back Day on October 29, 2011, turned in more than 377,086 pounds  
(188.5 tons) of unwanted or expired medications for safe and proper disposal at the 5,327 take-back sites that 
were available in all 50 states and U.S. territories. When the results of the three Take-Back Days to date are 
combined, the DEA and its state, local, and tribal law-enforcement and community partners have removed 995,185 
pounds (498.5 tons) of medication from circulation in the past 13 months.  
 
According to the Centers for Disease Control and Prevention, enough prescription painkillers were prescribed in 
2010 to medicate every American adult around-the-clock for one month.  Purging America’s home medicine 
cabinets of unwanted or expired medications is one of four action items outlined in the national   
        strategy for reducing prescription drug abuse and diversion.  
 
Excerpted from http://www.deadiversion.usdoj.gov/drug_disposal/takeback/takeback_102911.html 
STORAGE & DISPOSAL 
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1:13 Pharmacies may consider serving as medication disposal sites 
This recommendation is included to encourage exploration of opportunities to create a safe means 
to collect and dispose of unwanted medications to reduce environmental access and availability of 
prescription drugs.  Pharmacies, however, are precluded from serving as medication disposal sites 
by federal law that is currently under review for possible changes that may allow them to serve in 
this capacity in the future.  In the Safety & Law Enforcement section of this plan it is also noted 
that local police departments may serve as a secure location for permanent drop locations as they 






Prescription drug monitoring should be instituted by means of a centralized 
database accessible to prescribers and dispensers 
 
As of May 2011, Prescription Drug Monitoring Program (PMP) legislation has been adopted in 
48 of 50 states, leaving New Hampshire as one of two states in the country without an electronic 
database accessible to prescribers and dispensers to monitor a patient’s prescription drug history.  
Please see the Government section of this report for more information about the content and status 
of this pending legislation in New Hampshire.   
 
For more information about prescription drug monitoring,  







Prescribers and prescribing facilities may consider patient contracts  
and other protocols to monitor and detect prescription drug diversion 
and/or abuse 
 
Several health care practices in the state have instituted patient contracts or patient agreements for 
those patients who are being prescribed narcotics over a period of time for chronic conditions or 
for those patients who may have a history of or potential for prescription drug misuse or abuse.  
Contracts may require that patients only fill prescriptions at one specified pharmacy, that they 
submit to pill counts or urine testing when requested, or other measures to deter abuse.  Please see 
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Dispensers should take increased precautions to protect stock and prevent 
unlawful access to prescription drugs 
 
Pharmacies and other dispensaries are increasingly becoming targets 
of theft and fraud.  For example, in 2009, a Rite Aid pharmacy in 
Ossipee, NH, was burglarized four times by individuals seeking pain 
medication.  Enhanced safety precautions and anti-theft measures are 
necessary to increase the safety of pharmacists, pharmacy technicians 
and the public and to prevent unlawful access to controlled drugs. 
Although the quantity of prescription drugs being stolen from 
pharmacies is on the decline in New Hampshire
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, this may be due to 






Licensing boards and authorities should monitor, investigate and enforce 
policies and encourage enhanced protocols to deter abuse and diversion 
 
The New Hampshire Board of Pharmacy, the New 
Hampshire Board of Nursing, and the New 
Hampshire Board of Medicine all support the 
monitoring, investigation and enforcement of 
policies, laws and protocols to deter abuse and 
diversion.  Each provides access to professional 
development and training to support practitioners 
in ethical decision-making and abuse deterrence.  
Their training calendars are available on the web  
at the links provided at the end of this section. 
Licensing boards may also consider increasing 
public and professional awareness of how to 
register a concern regarding improper, unsafe, or 
questionable prescribing or dispensing practices.  
 
 
Weeks Medical Center – Lancaster, NH 
 
     Weeks Medical Center instituted patient contracts in 2010 for patients who were prescribed opioid pain relievers 
to treat chronic conditions. The contracts stipulated the risks associated with use and the consequences of violating 
the contract either as a result of misuse, abuse or diversion.  Patients who are found to  
be in violation of the contract are terminated as pain patients but may remain under 
the care of the medical center for other health care needs.  Please see Appendix C  
for a copy of the patient contract used by Weeks Medical Center. 
Ossipee 
SURVEILLANCE & MONITORING 
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 The New Hampshire 
 Board of Pharmacy 
issues Pharm-ALERTs that are faxed to all pharmacies with 
intelligence reports from state law enforcement regarding 
immediate threats.  The alerts provide the means of 
diversion (e.g. a stolen prescription pad from a specific 
hospital), the names under which fraudulent prescriptions 
have been sought, the doctor’s name being used on the 
prescription, and the drugs being sought. These alerts 
have been effective in notifying dispensers of fraudulent 
activity discovered by authorities.  
































Referral to appropriate intervention or treatment should be provided if 
indications of abuse or dependence exist 
 
One patient screening and referral model that has gained attention for its outcomes is the evidence-
based Screening, Brief Intervention and Referral to Treatment (SBIRT) approach endorsed by the 
U.S. Substance Abuse and Mental Health Administration (SAMHSA). The model encourages a 
brief screening for alcohol or other drug abuse in primary practice, emergency rooms, or other 
settings.  A screening indicating potential alcohol or drug abuse leads to an additional set of 
questions that determine if a practitioner should provide a brief intervention, such as motivational 
interviewing, or if referral to more intensive intervention or treatment is necessary.  Although 
some service delivery systems, such as the state’s community mental health system, does conduct 
brief alcohol and drug screenings of all clients, universal screening is not yet a widespread 
practice.  Attention should be given within other care systems, such as the community health 
center system and hospital emergency rooms, to implement screening and appropriate 
































SURVEILLANCE & MONITORING 
























Guidelines for the Use of Controlled Substances in the Treatment of Pain  






The New Hampshire Board of Nursing provides continuing education opportunities for nurses, including 






NH Department of Corrections, Division of Medical and Forensic Services, Clinical Guidelines for 




















The New Hampshire Board of Pharmacy provides continuing education for pharmacists and pharmacy 




















The American Society of Addiction Medicine introduced the Physician Clinical Support System for 
Primary Care (PCSS-P), a free, nationwide service to help primary care providers seeking to identify and 








Updated guidelines  





























The New Hampshire Department of Health and Human Services' Injury Prevention Program 
 
 http://www.dhhs.nh.gov/dphs/bchs/mch/injury.htm   
 
 
The Northern New England Poison Control Program - New Hampshire  
 
 http://www.mmc.org/mmc_body.cfm?id=3090  
 
 
Northeast Regional Injury Prevention Network - Poison Data Book (January 2004) 
 
 http://www.ask.hrsa.gov/downloads/poison_book.pdf  
 
 







The National Institute on Drug Abuse (NIDA) Centers of Excellence for Physician Information 
provides science-based resources to help physicians identify patient drug use early and to prevent it from 







Online Screening, Brief Intervention and Referral to Treatment (SBIRT) training through the National 































SCREENING & BRIEF INTERVENTIONS 
ADDICTION TREATMENT 












































SAFETY & LAW  
ENFORCEMENT 



















































Increase the number of trainings and professional development opportunities available to and 










2:3 Participate in local Take-Back events to collected unused or unwanted medication 





Continue and expand investigation and prosecution resources and efforts specific to 
prescription drug diversion 
2:6 
Designate an officer as a prescription drug diversion specialist for targeted training, 















Safety & Law Enforcement Recommendations Overview 
PUBLIC EDUCATION & AWARENESS 
STORAGE & DISPOSAL 




































Local Law Enforcement - Emergency Medical Technicians - First Responders 
Drug Diversion Specialists - Police Standards & Training  











According to Section 309 of the federal Uniform Controlled Substances Act, drug diversion is the 
transfer of a controlled substance from a lawful to an unlawful channel of distribution or use.  
Because prescription drugs are legal substances when prescribed, dispensed, and used 
appropriately, enforcement of drug diversion laws is unique and requires a proactive commitment 








Increase the number of trainings and professional development opportunities 
available to and accessed by law enforcement and other safety personnel 
 
Diversion of prescription medication from its original recipient and/or intent is unlawful and 
requires unique law enforcement practice strategies distinct from those developed for illicit drugs. 
Determining the means and methods by which drug-seekers may be acquiring prescription drugs 
requires specialized training and proactive enforcement.  Professional development and training 
for law enforcement and safety professionals should include training in prescription forgery and 
other diversion tactics such as doctor shopping, illicit prescription drug sales, and specialized 
investigation and enforcement.  The New Hampshire Department of Safety’s Drug Diversion Unit 
has developed a curriculum for trainings through the Police Standards and Training Council and 
other training providers.   
 
In addition, the New Hampshire Division of Liquor Enforcement is leading the state’s training 
effort relative to Drug Recognition Experts and Advanced Roadside Impairment Detection 
Enforcement (ARIDE) to help deter motor vehicle impairment due to prescription drug abuse or 
other substance abuse (See Commitments to Action on page 73).  The state’s federal partners also 
provide training opportunities for law enforcement.  Federal training partners include the New 
England High Intensity Drug Trafficking Area and the U.S. Drug Enforcement Agency.  Links to 






Safety & Law Enforcement Recommendations 








































Develop and disseminate legal bulletins specific to prescription drug abuse 
and diversion   
 
Legal bulletins can be an effective means to highlight the scope of the epidemic on a consistent 
basis and can be disseminated to a wide range of state and community stakeholders.  The New 
Hampshire Attorney General’s office and the New Hampshire Department of Safety are 
committed to summarizing prevalence and other statistics on prescription drug diversion and 
enforcement regularly to keep communities informed (see Commitments to Action on page 73).  
Local and county law enforcement agencies should consider similar practices to share information 
on investigations, prosecution, drug-seeking behaviors and tactics, and safety precautions.  Legal 
bulletins can be disseminated through existing list serves, fax alert networks, public health 
networks, social media, and other communication routes. 
 
   
 
2:3
Participate in local Take-Back events to collect unused or unwanted 
medication 
 
Take-Back events are defined by the U.S. Drug Enforcement Administration as organized 
collection events designed to reduce the amount of unwanted or unused pharmaceutical products 
that may pose a risk to public health and safety, that may be accessible to diversion, or that 
otherwise may be disposed of in a manner that does not comply with State or Federal laws or 
regulations.
30
  Once a controlled drug leaves the possession of the individual to whom it was 
prescribed, law enforcement are often the only institution with the legal authority to handle and 
dispose of the drugs.  Therefore, the participation of local and county law enforcement has been 
critical to the success of the three national Take-Back events that have been hosted in New 
Hampshire communities over the past 15 months.   
Because of legal concerns raised regarding the handling of the prescription drugs by individuals 
other than law enforcement during the Take-Back events, the New Hampshire Office of the 
Attorney General crafted legislation to accommodate the activities of the Take-Back events safely 
and legally.  This legislation, introduced as House Bill 71, was passed by the New Hampshire 
Legislature this year and allows for “communities and private entities in conjunction with law 
enforcement officers to establish controlled and non-controlled pharmaceutical drug take-back 
programs” and requires rulemaking by the Department of Justice, the Board of Pharmacy, the 
Department of Safety, and the Department of Environmental Services to provide established 
guidelines for such Take-Back events.  The legislation allows for individuals to drop off 
medications anonymously and lessens the disposal restrictions for drugs collected in this venue 
that are much more stringent as stipulated in RSA 318-B:17 for illicit drug disposal.
31
  The formal 
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2:4 Serve as permanent disposal sites for the public 
 
Many local police departments and safety units have supported local Take-Back initiatives in New 
Hampshire as one-time events, but several police departments across the state have or are 
considering serving as permanent drop-off locations for the public in support of prescription drug 
abuse prevention.  Local police departments have been meeting the challenge of the prescription 
drug diversion through specialized enforcement but are also committing resources to serve as 
permanent disposal sites because they are uniquely suited to do so through their authority to 
receive and properly dispose of controlled drugs.  In addition, locating a drop-box at a police 
department minimizes safety concerns relative to drug-seekers who may attempt to gain access to 
prescription drugs that have been dropped off for disposal. Once a permanent drop-off location is 
established, as in Keene, New Hampshire, local coalitions, health and medical professionals, 
schools, businesses, and other community organizations can begin to promote the site to the public 




Continue and expand investigation and prosecution resources and efforts 
specific to prescription drug diversion 
 
The new era of prescription drug diversion has demanded a quick and specialized response from 
the law enforcement and safety sector at a time when resources are scarce and the demands on 
local, county and state law enforcement are high.  Yet law enforcement officials in New 
Hampshire are more committed than ever to developing an adequate and effective response to the 
growing epidemic of prescription drug abuse.  This commitment has led to specialized trainings 
offered through the Department of Safety’s Drug Diversion Unit and through other state, regional 
and federal resources listed at the end of this section.  Local and county law enforcement and 
safety officials are called to prioritize the epidemic of prescription drug abuse through expanded or 
enhanced diversion enforcement and prosecution and to collaborate with local, state and federal 




Designate an officer as a prescription drug diversion specialist for targeted 
training, community liaison, intelligence bulletins, and coordination of effort 
 
Designating a specific officer(s) to serve as a liaison between state training and response efforts 
and community networks is an approach that has been successful with other alcohol and drug 
efforts such as underage drinking.  A designated officer can coordinate comprehensive training 
schedules within their local department, serve as a “train the trainer” to bring specialized resources 
to his/her department, serve on community task forces working to prevent and reduce prescription 
drug abuse, and serve as a conduit of bi-directional information sharing such as through legal 
bulletins or data mining and analysis.  A designated officer could also be trained as a Drug 
Recognition Expert to assist in prescription drug abuse cases when appropriate.  
 
SURVEILLANCE & MONITORING 
SURVEILLANCE & MONITORING 
STORAGE & DISPOSAL 











































































Community Spotlight: Take-Back Events in the Monadnock Region 
 For each of the three National Take-Back events held since the strategy was initiated by the 
U.S. Drug Enforcement Agency, Monadnock Voices for Prevention and its government partner,  
Cheshire County, have mobilized law enforcement agencies, schools, community organizations, 
health care partners and pharmacists to assist in the region-wide effort to reduce  
environmental access to prescription drugs by encouraging local residents to drop  
off unused medications at participating police departments.  The momentum has 
led to a permanent secure drop-off location at a local police department sponsored  
by a local Rotary Club.  In the Monadnock region, the one-day events have so far  
led to over 1,000 pounds of unused medications being safely disposed of.   
In the April 2011 Take-Back event, New Hampshire, with a population of only  
1.3 million collected 10% of all medications gathered across the U.S. in  
similar events that day.  For more information about Monadnock Voices for  
Prevention’s prescription drug abuse prevention efforts, please visit: 
  
  http://www.monadnockvoices.org 















































New England High Intensity Drug Trafficking Area (HIDTA) training opportunities 
 
 http://www.hidta.org/Training/training.asp  
 
 
U.S. Drug Enforcement Agency training opportunities 
 
 http://www.justice.gov/dea/programs/training/part8.html  
 
 
The NH Division of Liquor Enforcement drug recognition expert training program and alcohol/drug 
training for alcohol licensees 
 






























GENERAL TECHNICAL ASSISTANCE 
TAKE-BACK PROTOCOLS 




































































PROFESSIONAL DEVELOPMENT & TRAINING 









Increase the number of trainings and professional development opportunities available to 






Support the dissemination of public service announcements and bulletins to youth, 
students, parents, and communities relative to prescription drug misuse, abuse and 
diversion   
3:3 
Support the implementation of evidence-based health curricula that address prescription 





3:4 Help promote community Take-Back events to collect unused medication 
3:5 
Ensure that health and nursing services implement safe storage and dispensing of 





Continue school-based data collection to gauge the prevalence and perceptions of 
prescription drug misuse and abuse 
3:7 
Establish, communicate and enforce drug-free policies and comprehensive approaches that 
include prevention of prescription drug misuse or abuse 








SURVEILLANCE & MONITORING 
Education Recommendations Overview 


































School Safety Officers - Campus Health Services - School Nurses - Campus Police 
Student Assistance Counselors - College Counseling Departments  
Staff & Administration 
 











Increase the number of trainings and professional development opportunities 
available to and accessed by school personnel 
 
Professional development and training for school nurses, health teachers, health services staff, 
administrators, school safety officers, alcohol and drug counselors and other staff will increase 
awareness of prescription drug abuse as a preventable epidemic and will provide specific 
strategies that school- and college-based health and safety professionals can implement to address 
misuse and abuse effectively.  Training is available from a wide range of stakeholders in the state 
and region. Links to resources for the education sector are listed at the end of this section and 
throughout this report.  For example, the New Hampshire Board of Nursing provides online 
training for school and campus nurses while the New Hampshire Drug Diversion Unit provides 
training appropriate for school resource officers and campus police.  See also the Commitments to 
Action section of this document beginning on page 73 for the role of the New Hampshire 




Support the dissemination of public service announcements and bulletins 
to youth, students, parents, and communities relative to prescription drug 
misuse, abuse and diversion   
 
Public and private schools and institutions of higher education have effective, well-established 
communication channels that can be leveraged in service to the state’s Call to Action for the 
purposes of educating youth and young adults on the risks associated with prescription drug 
misuse, abuse and diversion.  During the development of this plan it was noted that youth 
leadership and advocacy groups such as local Youth to Youth, Project Success or Peer Outreach 
chapters can play an effective role in helping to communicate risks to their peers and the 
community-at-large.  Communication channels may take the form of newsletters, emails, open 
letters to parents or campus communities, websites, social media, poster campaigns, blogs, and 
other forms.  
Education Recommendations 
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It is recommended that schools, colleges and universities respond favorably to requests from state 
and community stakeholders to disseminate information on prescription drug abuse and actively 
schedule their own regular information dissemination on prescription drug abuse.  Sources of 





Support the implementation of evidence-based health curricula that address 
prescription drug misuse and abuse   
 
Elementary, middle and high schools as well as colleges and universities typically provide some 
form and duration of health education as a component to general education requirements. It is 
recommended that schools at all levels review their health curricula to ensure that alcohol and 
drug abuse is adequately covered as a health topic priority, that the curricula being used have 
evidence of effectiveness in increasing knowledge of risks (physical and otherwise) of alcohol 
abuse and drug use, and that the curricula specifically address prescription drug misuse and abuse.  
One comprehensive approach to prevention and early intervention that was implemented widely in 
New Hampshire schools before recent budget reductions is Project Success, an approach that 
combines youth and parent education with policy revision, more intensive prevention for high-risk 
populations, and early intervention strategies in the school setting.  Resources to assist schools in 





3:4 Help promote community Take-Back events to collect unused medication 
 
As mentioned in other sections of the Call to Action, Take-Back events were established by the 
U.S. Drug Enforcement Agency to reduce environmental access to prescription drugs that pose 
significant risk to those who may misuse or abuse them.  New Hampshire communities have 
participated in three such events over the last 15 months, with unprecedented amounts of 
medications collected and disposed of safely.  Schools can help promote these events to parents 







Ensure that health and nursing services implement safe storage and 
dispensing of medications to deter abuse or diversion 
 
As mentioned in the Health & Medical section of this document, safe storage of prescription 
medications is a means to deter abuse and diversion.  School and campus nursing or health 
services may store medications for students and monitor the dispensing of prescribed medications. 
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Continue school-based data collection to gauge the prevalence and 
perceptions of prescription drug misuse and abuse 
 
Valuable data are collected from youth and young adults through surveys administered in school 
settings in New Hampshire as these settings reach the widest cross-section of children and young 
adults.  The Youth Risk Behavior Survey, Teen Assessment Project survey, Communities That 
Care, and Pride surveys are all reliable instruments administered at the middle and high school 
level to collect local prevalence and perception data on alcohol and drug abuse, including 
prescription drug abuse.  Additionally, the New Hampshire Higher Education Consortia has an 
alcohol and other drug committee that oversees the administration of the New Hampshire Higher 
Education Alcohol, Tobacco and Other Drug Survey at participating colleges and universities. 
These biannual surveys provide valuable data to health and safety stakeholders to design effective, 
data-driven responses to alcohol and drug abuse risks and trends. It is recommended that schools 
continue to allow for this data collection in school settings and to support the use of data to inform 






Establish, communicate and enforce drug-free policies and comprehensive 
approaches that include prevention of prescription drug misuse or abuse 
 
Comprehensive school-based approaches to substance abuse include effective, well-monitored and 
consistently enforced policies to define, prevent, intervene in and appropriately address alcohol 
and other drug problems.  As mentioned earlier in this section, Project Success is an evidence-
based comprehensive approach that many New Hampshire schools have adopted to incorporate 
youth leadership, parent education, policy change and enforcement, early intervention for high-
risk youth populations, and referral to treatment or recovery services for students with identified 






Provide problem identification and referral for youth and adults within the 
educational systems 
 
Problem identification and referral has been an effective approach to addressing alcohol abuse and 
drug use with those misusing and abusing substances.  Schools, colleges and universities are in a 
unique position to identify individuals early and to provide brief interventions or referrals to more 
comprehensive services.  In the Health & Medical section of this report, an evidence-based 
approach to problem identification and referral known as SBIRT (Screening, Brief Intervention 
and Referral to Treatment) is presented as one approach that has strong evidence of effectiveness 
in emergency room and primary care settings.  SBIRT or a similar approach can be applied in 
school settings when a student is found to be in violation of an alcohol or drug policy or who 
requires medical attention as a result of alcohol abuse or drug use, including prescription drug 
misuse or abuse.  
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The New Hampshire Board of Nursing provides continuing education opportunities for nurses, including 









The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA)’s SBIRT initiative 
has included grant programs, policy briefs, and training to encourage the implementation of SBIRT in a 

















The NH Division of Liquor Enforcement drug recognition expert training program and alcohol/drug 
training for alcohol licensees 
 






U.S. Department of Education’s Higher Education Center for Alcohol, Drug and Violence Prevention 







The White House Office of National Drug Control Policy oversees “Parents – the Anti-Drug” and other 
education and awareness campaigns, providing web links, print materials and other resources to support 
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DRUG DIVERSION 
PRESCRIBING & MONITORING 
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Increase the number of trainings and professional development opportunities available to 










4:3 Help promote community Take-Back events to collect unused medication 
4:4 
Ensure that worksite policies and practices articulate safe storage and use of medications to 





Establish, communicate and enforce drug-free workplace policies that include prevention 
of prescription drug misuse or abuse 
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Risk Management - Health Educators - Employee Assistance Programs 
Safety Compliance Officers - Human Resource Departments 
Senior Management - Business Owners & Operators 












Employers are often as affected by the substance use of their employees as the employees’ 
families and friends.  Of the estimated 19.3 million current illicit drug users aged 18 or older in 
2009, 12.9 million (66.6%) were employed either full- or part-time.
32
 The effects of workers who 
abuse alcohol, prescription medications or illicit drugs can range from lost work time to unsafe 
work conditions.  Employers, however, hold powerful tools and leverage to prevent and deter 
substance use through workplace policies and employee assistance programs. The following 
strategies are recommended for businesses and employers to consider in support of the state’s 
commitment to prevent and reduce prescription drug misuse and abuse and its harmful 







Increase the number of trainings and professional development opportunities 
available to and accessed by the workforce and employers 
 
Professional development and training provide education and strategies to ensure workers are 
aware of the risks of prescription drug abuse and the consequences of misuse and abuse in the 
workplace.  Professional development and training of risk managers, supervisors, and human 






4:2 Promote public education and awareness within the workplace    
 
Businesses can support public education and awareness through regular employee education 
programs that focus on worksite wellness and safety.  Company websites and health and wellness 
initiatives offered by employers can be a means to communicate information about the health risks 




PUBLIC EDUCATION & AWARENESS 



























4:3 Help promote community Take-Back events to collect unused medication 
 
Businesses, particularly those in the health or safety field, can help promote community Take-
Back events and even contribute resources for their successful implementation.  Resources may 
take the form of sponsorship of space, promotional materials, or equipment to support such events.  
For example, a local Rotary Club in the Keene, NH area provided funding to support a permanent 






Ensure that worksite policies and practices articulate safe storage and use 
of medications to deter abuse or diversion   
 
Employers can promote safe storage and medication use at job sites to deter abuse or diversion.  
Policies may require that employees inform employers if they are taking prescribed narcotics 
during work hours and receive guidelines on how and where to store and access medications on 
the job site when necessary.  It is critical, however, that employers respect employees' rights and 






Establish, communicate and enforce drug-free workplace policies that 
include prevention of prescription drug misuse or abuse 
Model workplace policies include educating employees about the health and productivity hazards 
of alcohol abuse, prescription drug misuse and abuse, and illicit drug use.  Company wellness 
programs and employee assistance programs can be leveraged to communicate company policies 
and ongoing health and safety promotion.  More comprehensive policies may also include 
mandatory random drug testing; clearly communicated consequences for any alcohol or drug 
abuse; rules for how and where allowable prescription drugs should be stored or accessed during 
work hours; mandatory participation in regular education programs regarding the harm of 
addiction and the impact of substance use on worker productivity, workplace safety, and other 






4:6 Provide problem identification and referral for employees 
 
As noted in previous sections of this document, problem identification and referral is an important 
strategy in protecting individuals’ health and safety.  Through employee assistance programs or 
more informal arrangements within small businesses, brief conversations can allow employers and 
supervisors to identify and respond to problems early on.  If an employee is at risk of developing a 
serious problem, he/she may receive a brief intervention that focuses on raising their awareness of 
substance abuse risks and motivating them to change their behavior while those who may need 
more extensive treatment receive referrals to specialty care.
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SURVEILLANCE & MONITORING 
SURVEILLANCE & MONITORING 
STORAGE & DISPOSAL 
STORAGE & DISPOSAL 



















U.S. Department of Labor “Policy Builder” provides guidance in developing and maintaining an 









U.S. Department of Labor Employee Education curriculum provides employee education modules on 
drugs and alcohol in the workplace, including business impact and safety.  Download educational programs 







“Prescription Drug Abuse in the Workplace” – a publication of the U.S. Substance Abuse and Mental 




















































































PUBLIC EDUCATION & AWARENESS 













5:2 Lead and/or support a public awareness campaign 
5:3 
Identify, promote and support evidence-based programs, policies and practices that 














5:5 Pass legislation to implement an electronic Prescription Drug Monitoring Program  
5:6 
Adjust existing state-level data collection to provide greater detail relative to the 
prevalence, causes, sources, and consequences of prescription drug abuse 
5:7 






Provide reimbursement to health and medical practitioners for Screening, Brief 
Intervention and Referral to Treatment (SBIRT) 
5:9 
Expand funding for treatment to increase access for individuals requiring treatment for 
prescription drug abuse 
5:10 
Consider specialized or “therapeutic” courts that provide culturally sensitive assessments, 
treatment and recovery opportunities in place of traditional probation or incarceration 
SURVEILLANCE & MONITORING 
Government Recommendations Overview 









































Local, county and state governments play a critical role in addressing the prescription drug abuse 
epidemic in that they are able to develop effective population-level laws and regulations and to 
direct resources to meet identified needs.  In spite of the difficult economic pressures at all levels 
of government, lawmakers and elected officials can also bring much needed visibility, leadership, 
legislation, and collective commitment to combat the growing epidemic in New Hampshire. 







Support licensing boards in addressing concerns relative to prescribing and 
dispensing controlled drugs 
The state government sector provides necessary oversight of prescribing and dispensing practices 
through its licensing boards.  In New Hampshire, the Board of Medicine, the Board of Nursing 
and the Board of Pharmacy exist for the safety and protection of New Hampshire citizens.  In light 
of the epidemic of prescription drug abuse it is recommended that government leaders and 
lawmakers ensure licensing boards have sufficient resources and authority to protect citizens 
through well-monitored and enforced prescribing and dispensing practices. Licensing boards 







5:2 Lead and/or support a public awareness campaign 
 
The New Hampshire Bureau of Drug and Alcohol Services and the public education and 
awareness task force of the Governor’s Commission on Alcohol and Drug Abuse work closely 
with the Partnership for a Drug Free New Hampshire and the National Guard Counterdrug Task 
Force to develop and disseminate public media campaigns and other public service announcements 
to prevent and reduce alcohol abuse and other drug use.  Continuing and expanding the capacity of 
these partnerships and efforts in order to increase the public’s awareness of the dangers of 
prescription drug misuse, abuse and diversion is a critical component of an effective state 
prevention strategy.  All state agencies and divisions can assist in the dissemination of public 
service announcements and campaigns relative to prescription drug abuse in service to this Call to 
Action.  
State Lawmakers - County Officials  
Local Governance - State Agencies & Commissions 
Government Recommendations 
PUBLIC EDUCATION & AWARENESS 
PRESCRIBING & DISPENSING 





























Identify, promote and support evidence-based programs, policies and 
practices that communities can adopt to deter abuse 
 
Through the Bureau of Drug and Alcohol Services and its training and technical assistance 
contractors, evidence-based programs, policies and practices for schools, businesses, police 
departments, medical practices, and other community sectors can be identified and promoted.   
In addition, the Bureau’s Regional Network System can be mobilized to support community 
sectors in their adoption of evidence-based prevention, intervention, and treatment policies and 
programs.  Other state agencies such as the New Hampshire Department of Safety, the Department 
of Health and Human Services, the Department of Education, the National Guard, the Attorney 
General’s Office, state licensing boards, and others may also identify and promote evidence-based 






Continue to support state and local opportunities to collect and safely 
dispose of unused medication 
 
As mentioned in the Safety & Enforcement section of this document, the New Hampshire Attorney 
General supported the passage of legislation (House Bill 71) to allow communities and private 
entities in conjunction with law enforcement to conduct local pharmaceutical drug Take-Back 
events and programs to collect, store, and dispose of unused controlled and uncontrolled 
prescription drugs in a safe and effective manner.  The legislation allows for individuals to drop 
off medications anonymously and lessens the disposal restrictions for drugs collected in this venue 
that are much more stringent as stipulated in RSA 318-B:17 for illicit drug disposal.
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  At this 





Pass legislation to implement an electronic Prescription Drug Monitoring 
Program  
 
Legislation to allow for the establishment of an electronic controlled drug prescription monitoring 
program (PMP) will provide prescribers and dispensers timely access to information for the 
purposes of monitoring patients’ prescriptions.  Federal guidelines recommend that Schedule II 
through V medications be included in PMPs, although current pending legislation in New 
Hampshire includes Schedule II and III drugs only (Please see Appendix G for a list of controlled 
drugs by schedule classification).  Legislation has been submitted and considered each year since 
2008 and is currently in interim study as House Bill 332-FN.  The most recent version of the 
house-initiated legislation recognizes that prescription drug abuse is a significant problem in the 
state and that individuals with substance use disorders may seek controlled drugs from health care 
providers. It also articulates that “allowing providers to have access to information suggesting that 




SURVEILLANCE & MONITORING 
PUBLIC EDUCATION & AWARENESS 
STORAGE & DISPOSAL 























In December of 2011, the New Hampshire Senate also introduced PMP legislation (SB 286) titled, 
Controlled Drug Prescription Health and Safety Program.  The recently filed bill states the 
General Court’s belief that:   
 
A controlled drug prescription health and safety program that fully complies with 
all state and federal Health Insurance Portability and Accountability Act (HIPPA) 





The bill further states that: 
 
a controlled drug prescription health and safety program will reduce patient 
morbidity and mortality associated with controlled drugs by providing a secure 
program through which the prescriber and the dispenser may access information on 
a patient’s controlled drug prescription history. The program established by this act 
is designed to create a greater sense of safety, security, and comfort in the health 




This newly pending legislation in New Hampshire is to include Schedule II through IV controlled 
drugs and is sponsored by 15 of the state’s 24 senators. 
   
The effectiveness of prescription drug monitoring programs has been documented by independent 
evaluations of individual states’ programs and by researchers working under contract with the 
U.S. Department of Justice.  In an independent evaluation of 
Kentucky’s PMP program known as KASPER, the University of 
Kentucky documented the state’s adoption of a PMP program in 
1998 and its enhancement in 2005 to a 24 hour real-time accessible 
system (eKASPER). The evaluation found that 86% of prescribers 
using the system indicated the information either confirmed a 
decision to prescribe a controlled drug or altered their decision.  
Only 4% of prescribers who utilized the system indicated that the 




In an evaluation of 20 states’ PMP programs commissioned by the U.S. Department of Justice, 
researchers examined outcomes by PMP type, noting important distinctions between states with 
reactive versus proactive monitoring programs.  The researchers defined “reactive” programs as 
those generating "solicited reports" only in response to a specific inquiry made by a prescriber, 
dispenser, or other party with appropriate authority, whereas "proactive" programs were defined as 
those generating "unsolicited reports" for identification or investigation or when the system 
deemed it was warranted.  In this evaluation, researchers found that the presence of a PMP is 
associated statistically with a reduction in the per capita supply of prescription pain relievers and 
stimulants, and that this in turn reduces the probability of abuse.  This finding was evident in states 




































PMP legislation and resulting implementation of electronic systems to provide access to data on 
prescriptions being written and filled for individuals is one of the most universally recommended 
and adopted strategies by state governments to combat prescription drug misuse, abuse and 




























Adjust existing state-level data collection to provide greater detail relative 
to the prevalence, causes, sources, and consequences of prescription drug 
abuse 
 
The State of New Hampshire collects data regularly on the prevalence and perception of 
prescription drug misuse and abuse including surveys, death data, criminal offenses, and hospital 
and emergency room admissions and discharges. Survey-based data collection includes the state 
sample and local sample administration of the Youth Risk Behavior Survey (YRBS) of high 
school aged youth and the Behavioral Risk Factor Surveillance System (BRFSS) survey of adults 
in New Hampshire.  The YRBS is a paper survey completed in a school setting and overseen by 
the New Hampshire Department of Education.  The BRFSS is a phone survey conducted by the 
New Hampshire Department of Health and Human Services through the University of New 
Hampshire Survey Center.  National and federal recommendations include the adjustment of 
survey questions to better differentiate misuse from abuse.  Data are also collected by the New 
Hampshire Medical Examiner and the New Hampshire Department of Safety.  Currently, existing 
state-level data collection such as during emergency room admissions or local police arrests may 
not provide adequate specificity for data mining relative to prescription drug misuse, abuse and 
diversion.  Therefore, it is recommended that existing data collection efforts be expanded and/or 
enhanced to better monitor and respond to prescription drug misuse, abuse and diversion.  
 
 
SURVEILLANCE & MONITORING 




























Provide leadership and oversight in coordinated state-level surveillance, 
monitoring and strategic planning 
 
The New Hampshire Governor’s Commission on Alcohol and Drug Abuse Prevention, 
Intervention and Treatment provides the structure and process for ongoing leadership and 
oversight of state-level surveillance, monitoring and strategic planning relative to prescription 
drug abuse.  Its relationship to the State Epidemiological Outcome Workgroup for behavioral 
health and its prevention, treatment, public education and awareness, and health care task forces 
should be leveraged to provide integrated and coordinated surveillance and monitoring of the 
population-level data relative to prescription drug abuse as well as of the activities of community 
stakeholders and state agencies in support of this Call to Action.  The Commission will determine 
if its current structure and operations will provide adequate leadership or oversight or if a special 
task force will be formed to provide an opportunity for state agencies and partnerships to provide 
activity updates relative to this Call to Action. Additionally, the Commission is responsible for the 
development and implementation of the state’s five-year strategic plan to prevent, reduce and treat 
substance use disorders, currently slated for revision and publication in the fall of 2012.  It is 
anticipated that prescription drug abuse prevention, intervention and treatment will be prominent 






Provide reimbursement to health and medical practitioners for Screening, 
Brief Intervention and Referral to Treatment (SBIRT) 
 
Although financial resources are scarce for new initiatives, it is recommended that state 
government consider means to reimburse health and medical practitioners for SBIRT, explained in 
greater detail in the Health & Medical section of this document.  Some private insurance plans 
include such reimbursement which, when coupled with necessary training and technical 
assistance, provides an incentive for prescribers to screen for alcohol or other drug problems, 
including prescription drug abuse, and to help patients recognize their own risk of abuse and to 
seek specialized care if a substance use disorder is evident. The federal Affordable Care Act may 






Expand funding for treatment to increase access for individuals requiring 
treatment for prescription drug abuse 
 
With the increase in individuals presenting in state-funded treatment programs for prescription 
drug abuse, sufficient capacity to effectively treat substance use disorders, particularly addiction to 
opioids, is critical.  Treatment provides an opportunity for those struggling with addiction and 
dependence to receive effective and culturally sensitive care, to better manage mental and 
behavioral health conditions, and to restore their quality of life.  
 
SURVEILLANCE & MONITORING 
RESOURCE DEVELOPMENT 
SURVEILLANCE & MONITORING 


























List of locations where drug courts and mental 







Consider specialized or “therapeutic” courts that provide culturally sensitive 
assessments, treatment and recovery opportunities in place of traditional 
probation or incarceration 
 





 exist in several court 
systems throughout the state.  During the 
Prescription Drug Abuse Strategy Summit in 
October 2011, it was noted that the legislature 
had considered increasing the availability of 
drug courts throughout the state but that federal 
or other resources would be needed to 
implement this strategy.  It was also noted that 
many intervention programs that in previous 
years provided education and treatment 
resources in place of traditional probation or 
incarceration have closed due to budget 
reductions but that leadership within the New 
Hampshire Superior Court system is promoting 
innovative approaches to alternative sentencing 


























 Concord:  Drug Court (juvenile offenders only)  
 Mental Health Court   
Nashua: Drug Court (juvenile offenders) 
 Mental Health Court   
Exeter:  Mental Health Court   
Portsmouth: Mental Health Court   
Grafton: Adult Felony Drug Court  
Laconia: Drug Court (juvenile offenders only)  
Lebanon:  Mental Health Court 
Littleton:  Mental Health Court 
Manchester:  Mental Health Court     
Keene:  Mental Health Court   
Rochester:  Mental Health Court   
Rockingham: Adult Felony Drug Court  
Strafford: Adult Felony Drug Court   
SOURCE: http://www.courts.state.nh.us/drugcourts/index.htm 

















































































































































































Special populations affected by prescription drug abuse include military personnel, individuals re-
entering communities from correctional facilities, and older adults.  Below are presented some 
data available for each focus population and strategies and resources recommended to address 
prescription drug abuse with each population of focus.  Other focus populations and specific 






- Between 2002 and 2005, prescription drug abuse among military personnel doubled; and 




- According to New Hampshire National Guard statistics, during Fiscal Year 2010, there were 
39 substance abuse referrals into the Prevention, Treatment, and Outreach (PTO) program and 







Continue implementation of the comprehensive policy within armed forces that prohibits 
abusing any substance including prescription medications 
 
Continue required annual training for service members relative to prescription drug abuse, 
alcohol use and other drug use. 
 
Continue to disseminate “Harmful Interactions of Prescription Drugs” pamphlets and other 
materials relative to the risks and early warning signs of prescription drug abuse 
 
Continue random urinalysis testing to deter and intervene early in potential prescription 
drug abuse   
 
Continue to promote the PTO program as a service available to all members of the military 
needing help with alcohol abuse or drug use 
 
Through either self-referral or a positive urinalysis, continue to develop and monitor 



































During 2010, 1,158 state prison inmates were screened for substance use disorders.  Of those 








Connect re-entry population with primary care settings and/or health homes, sharing re-
entry plans with care providers including considerations for alcohol or drug abuse history, 
treatment, and recovery plans 
 
Consider special protocols for those working with re-entry populations in relapse prevention 
response 
 
Educate re-entry population on risks of prescription drug misuse and abuse within the 
context of health promotion and the prevention of relapse and/or recidivism 
 
Educate primary and specialty health and medical professionals in culturally sensitive care 
for re-entry populations 
 







According to the National Institute on Drug Abuse, individuals aged 65 years and older comprise 
only 13 percent of the population, yet account for more than one-third of total outpatient spending 
on prescription medications in the United States.
45
  Because older populations are more likely to 
be prescribed long-term and multiple prescriptions and more likely to experience cognitive 
decline, the potential for medication misuse may be heightened.  Fixed incomes, interactions with 
alcohol consumption, age-related metabolism changes, untreated health conditions, over-the-
counter medications, and other contributing factors may increase the risk of harm related to 
prescription drug use for older adults.   
In New Hampshire, in 2010 deaths related to drug abuse, including prescription drug abuse, were 
most prevalent in the 41 to 50 year old age range, followed by the 51-60 year old age range.
46
  
Special attention should be given by prescribers, dispensers, and health educators to the prevention 

























Programs unique to New Hampshire, such as the REAP program, provide in-home based 
counseling to older adults in mental, emotional and physical health promotion and risk 
prevention.  These and other programs within primary care may be tapped for increased 
education and awareness among older adults who may be a higher risk for prescription 
drug misuse and/or abuse. 
Health education and patient counseling sensitive to the unique conditions of older adults 
should be developed and implemented in a wide range of care settings, including hospitals, 
long-term care facilities, assisted living communities, and home- and community-based 
support systems. 
Problem identification and referral, such as Screening, Brief Intervention and Referral to 
Treatment (SBIRT) described in other sections of this report, may provide important 
opportunities for physicians, nurse practitioners, social workers, health educators, and 
other professionals working with older adults to increase awareness among older adults of 



























































by State Agency or Stakeholder 
  
 
This section of the Call to Action presents action plans developed and endorsed by key 
stakeholders and member agencies of the Governor’s Commission on Alcohol and Drug Abuse 
Prevention, Intervention and Treatment in service to the plan’s goals.  The Commission may 
establish a task force in 2012 to ensure ongoing implementation of action plans, collaboration in 
support of the shared commitments, and monitoring of activities and trend data to determine 




































Key stakeholder & member agencies committing to specific action in 
service to the Call to Action: 
 
Adjutant General of the New Hampshire National Guard 
New Hampshire Office of the Attorney General 
New Hampshire Board of Medicine 
New Hampshire Board of Pharmacy 
New Hampshire Bureau of Drug & Alcohol Services 
New Hampshire Department of Corrections 
New Hampshire Department of Education 
New Hampshire Department of Safety 
New Hampshire Division of Liquor Enforcement 
New Hampshire Division of Public Health Services 
New Hampshire Medical Society 
Commitments to Action 
 




























The New Hampshire Office of the Adjutant General is committed the following objectives in 
service to the state plan to prevent and reduce prescription medication misuse, misdirection and 
abuse. 
 
PUBLIC EDUCATION & AWARENESS 
Commitment Action Indicator(s) Time Frame Notes 
6:1 Continue Guard efforts to educate 
its soldiers and airmen about 
prescription drug abuse 
Number of Guard 
members trained 
SFY 2012 & 
ongoing 
Existing training requirements for members of 
the NH National Guard may be leveraged to 
increase knowledge of prescription drug abuse. 
6:2 Continue Guard efforts to support 
community coalitions and 
increase public awareness 
through the Guard’s Counter Drug 
Task Force  
Number of community 
coalition assistance  
requests supported by 
the Guard 
SFY 2012 & 
ongoing 
Members of the Guard’s Counterdrug Task Force 
are currently assigned to the NH Bureau of Drug 
and Alcohol Services to support community 
coalition development through direct educational 
programs, information dissemination, media 
messaging, and technical assistance in support of 
community engagement in prevention. 
STORAGE & DISPOSAL 
Commitment Action Indicator(s) Time Frame Notes 
6:3 Continue Guard efforts to support 
state-wide Take-Back events to 




Back events and 
outcomes 
SFY 2012 & 
ongoing 
The NH National Guard has been supporting 
state-wide Take-Back events since the 
strategy’s inception in 2010. Three state-wide 
events have been held in NH since 2010 in 
conjunction with federally designated dates. 
SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
6:4 Continue random drug testing and 
reporting for prescription drug 
misuse and abuse among Guard 
members 
Data from annual 
drug testing 
SFY 2012 & 
ongoing 
Department of Defense members regularly 
submit to random urinalysis testing. It is 
anticipated that testing for hydrocodone and 
benzodiazepine use will be added to the 
standard drug testing panel during federal FY’12. 
6:5 Continue Guard efforts to provide 
federal, state, and local law 
enforcement agencies with 





SFY 2012 & 
ongoing 
The NH National Counterdrug Task Force 
currently provides investigative case and 
analyst support to numerous law enforcement 
agencies operating in the State of NH. 
PROBLEM IDENTIFICATION & REFERRAL 
 Commitment Action Indicator(s) Time Frame Notes 
6:6 Leverage existing counseling 
services and Access to Recovery 
(ATR) care coordination for Guard 
members referred for intervention 
or treatment  
Number of Guard members 
educated about the referral 
process and counseling/ 
treatment services available 
SFY 2012 & 
ongoing 
ATR provides assessments and care 
coordination to support treatment 
and recovery plans for those Guard 
members with a diagnosable 
substance use disorder. 
 




























The New Hampshire Office of the Attorney General will be responsible for the following 
objectives in service to the state plan to prevent and reduce prescription medication misuse, 
misdirection and abuse.
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
7:1 Increase the number of trainings 
and professional development 
opportunities available to and 
accessed by law enforcement & 
other safety personnel by a 
minimum of 2 per year  
Number and participation 
of trainings/professional 




SFY 2012 & 
ongoing 
The AG works in partnership with Policy 
Standards and Training Unit (PTSU) and other 
training organizations.  
 
Topics to include: Enforcing DWI laws 
applicable to influence of Rx drugs, 
investigating Rx drug forgery cases. 
7:2 Co-develop and provide 
collaborative trainings with 
multiple stakeholders 
Number of trainings 
developed, offered and 
accessed 
SFY 2013 & 
ongoing 
This action requires funding or in-kind 
resources including partnerships with training 
centers for key constituencies (e.g. health care 
professionals, safety & law enforcement, 
community coalitions/ networks, public health, 
businesses, health educators, and others). 
PUBLIC EDUCATION & AWARENESS  
Commitment Action Indicator(s) Time Frame Notes 
7:3 Develop and disseminate Legal 
Bulletins specific to Rx Drug Abuse 
using the existing resources of 





SFY 2013 & 
ongoing 
This action will be implemented in partnership with 
New Hampshire Intelligence and Analysis Center 
(NHIAC), a clearinghouse developed to function as a 
focal point of two-way communication amongst all 
partners and other state agency information 
dissemination channels. 
STORAGE & DISPOSAL  
 Commitment Action Indicator(s) Time Frame Notes 
7:4 Support legislative 
rulemaking for 
“cooperative action” 
relative to periodic 
community and/or state Rx 




SFY 2012 & 
ongoing 
The formal rulemaking process has been initiated by 
the Department of Justice. The rulemaking process 
generally takes several months to complete, 
requiring a public hearing, a review by attorneys at 
the Office of Legislative Services, preparation of fiscal 
impact statements by state agencies, and a hearing 
before the Legislature’s Joint Legislative Committee 
on Administrative Rules. 
7:5 Provide  leadership, 
partnership, and support  
as needed to encourage 
periodic community-level  







Data on Rx Take-Back 
events and outcomes 
SFY 2012 & 
ongoing 
This action will rely on partnerships with local law 
enforcement, federal law enforcement (DEA), 
prescribers, pharmacists, and community 
organizations and networks. 
 
New Hampshire Office of the Attorney General 
 



















SURVEILLANCE & MONITORING 
Commitment Action Indicator(s) Time Frame Notes 
7:6 Institute prescription drug 
monitoring program for 




SFY 2012 & 
ongoing 
The Attorney General’s Office continues to 
proactively support legislative initiatives to 




















































The new Hampshire Board of medicine oversees licensing disciplinary action relative to 
physicians (M.D. and D.O.) and physician assistants (P.A.) practicing medicine in the State of 
New Hampshire.  The Board investigates complaints and issues disciplinary action when 
appropriate.  The Board is also involved in legislative policy and advocacy and the cultivation of 
continuing education for licensees.  The New Hampshire Board of Medicine is committed to the 
following objectives in service to the state plan to prevent and reduce prescription medication 
misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
8:1 Increase availability of and 
access to continuing education 
for licensees relative to 
prescribing of opioids 
Number of trainings/ 
professional development 
offered and accessed by 
prescribers 
SFY 2012 & 
ongoing 
Currently working with Boston University 
Medical School to bring training resources to 
NH licensees 
8:2 Increase availability and access 
to continuing education through 
cross-training of prescribers, 
specialty care, behavioral  
health/ addiction treatment, law 
enforcement and others 
Number of trainings/ 
professional development 
offered and accessed by 
prescribers 
SFY 2012 & 
ongoing 
Collaborative may emerge through 
prescription drug task force and will likely 
include relationships with the Board of 
Pharmacy, the Drug Diversion Unit, the 
Medical Society, and the Board of Nursing 
PUBLIC EDUCATION & AWARENESS  
Commitment Action Indicator(s) Time Frame Notes 
8:3 Promote public education and awareness 
about the role of the Board of Medicine 




SFY 2012 & 
ongoing 
Current website provides 
information to the public on how to 
file a complaint 
SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
8:4 Support legislation relative to 
electronic access to patient 




SFY 2012 & 
ongoing 
Board of Medicine has and will testify in 











































The NH Board of Pharmacy inspects and investigates consumer and professional complaints 
against licensees or registrants. The Board of Pharmacy maintains five full-time staff to regulate 
301 in-state pharmacies; 386 out-of-state pharmacies; 2,355 NH-licensed pharmacists; 2,329 NH-
registered pharmacy technicians; 994 manufacturers and distributors; and 106 limited drug 
distributors.  The Board of Pharmacy also conducts inspections of pain clinics in New Hampshire.  
The New Hampshire Board of Pharmacy is committed to the following activities in service to the 
state plan to prevent and reduce prescription medication misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
9:1 Increase the number of trainings 
and professional development 
opportunities accessed by 
pharmacists by a minimum of 2 
per year 
Number of trainings/ 
professional development 




SFY 2012 & 
ongoing 
Training topics will include Pharmacist-In-
Charge responsibilities, Rx Patrol, fraudulent 
scripts, and other drug-seeking scams, Rx drug 
disposal/DEA Take-Back events and 
opportunities, challenges in pain management, 
PharmAssist program (impairment recovery 
program for pharmacists), and other trainings 
to deter abuse and drug diversion. 
PUBLIC EDUCATION & AWARENESS  
Commitment Action Indicator(s) Time Frame Notes 
9:2 Develop a web portal for pharmacists and 
prescribers to share general information 
about problems and solutions relative to 
Rx drug abuse and diversion 
Web portal live and 
accessible to pharmacists 
& prescribers 
SFY 2012 & 
ongoing 
This action item will not be 
actionable until funding or in-kind 
resources become available. 
9:3 Update and disseminate the “Pharmacy 
Diversion Alert!” document to 
pharmacists and pharmacy staff 
Manual updated and 
disseminated 
SFY 2012 & 
ongoing 
The Board of Pharmacy will explore 
funding opportunities to implement 
this action. 
 
9:4 Develop and implement a “Pharmacy of 
the Month” program to educate 
pharmacies in best practices and to 
recognize successes in deterring Rx drug 
abuse 
Program initiated and 
operational 
 
SFY 2013 & 
ongoing 
The Board of Pharmacy will explore 
funding opportunities to implement 
this activity. 
 
STORAGE & DISPOSAL 
Commitment Action Indicator(s) Time Frame Notes 
9:5 Develop and provide collaborative 
trainings with multiple stakeholders 
Number of trainings 
developed & accessed 
 
SFY 2013 & 
ongoing 
This action requires funding or in-kind 
resources including partnerships with the  






New Hampshire Board of Pharmacy 
 



















SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
9:6 Increase investigations of pharmacies 





SFY 2012 & 
ongoing 
Funding will be required to increase 
investigative resources. 
 
POLICY & LEGISLATION 
Commitment Action Indicator(s) Time Frame Notes 
9:7 Work with the Attorney General’s 
office to consider and/or introduce 
legislation to limit an individual’s 
ability to fill a prescription written 
outside of the northeast to one fill 





SFY 2012 & 
ongoing 
This action is under consideration due to 
pharmacist concerns regarding the  
prevalence and pattern of prescriptions 
being seen from Florida and other states.  
The action may not be necessary if PMP 
legislation is passed. 
 


















As the federal Single State Authority designee for alcohol and drug abuse efforts, the New 
Hampshire Bureau of Drug and Alcohol Services has its primary mission to reduce alcohol and 
other drug misuse and its social, health, and behavioral consequences for the citizens of New 
Hampshire through public policy and resource development, education, and by supporting 
initiatives that ensure the delivery of effective and coordinated prevention, intervention, treatment 
and recovery support services.  The Bureau carries out its mission through a system of regional 
networks focused on community strategies to prevent alcohol and other drug abuse, including the 
misuse of prescription drugs, as well as through technical assistance, training, public information, 
treatment services and recovery supports to provide an effective continuum of care for 
individuals, families and communities. 
 
Through its mission and service array, the Bureau is well poised to implement and promote state-, 
community- and provider-level strategies in service to the growing problem of prescription drug 
misuse and abuse. The New Hampshire Bureau of Drug and Alcohol Services is committed to the 
following objectives in service to the state plan to prevent and reduce prescription medication 
misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
10:1 Increase the number and reach 
of training and professional 
development relative to 
evidence-based approaches to 
prescription drug misuse, 
including but not limited to 
opioid abuse 
Number of trainings 
offered and accessed 





SFY 2013 & 
ongoing 
This action will seek to increasing training 
opportunities through existing resources such 
as the New Hampshire Training Institute on 
Addictive Disorders contractor, the New 
England School of Addiction Studies, state 
partners, the community college and 
university system, federal technical 
assistance systems, and other stakeholders.  
 
10:2 Strengthen partnerships and 
capacity of state-funded 
treatment providers and primary 
care in support of medication-






SFY 2013 & 
ongoing 
This action will leverage systems change 
opportunities of the Affordable Care Act (ACA) 
to strengthen partnerships between and 
capacity of addiction treatment and primary 
care. 
 
STORAGE & DISPOSAL  
 Commitment Action Indicator(s) Time Frame Notes 
10:3 Continue to encourage the 
Regional Network System to 
facilitate and/or support 
community Take-Back events to 
collect unwanted Rx drugs 
Data on Regional 
Network-supported Rx 
Take-Back events and 
outcomes 
 
SFY 2012 & 
ongoing 
Efforts are already being undertaken by the 
Regional Network System and have been 
highlighted during Governor’s Commission 
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SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
10:4 Expand public education and 
awareness activities specific to Rx 
drug abuse prevention, intervention, 
treatment and recovery  
Dissemination of Rx 




SFY 2012 & 
ongoing 
This action will leverage the existing 
capacity of Partnership for a Drug Free NH, 
the Bureau’s Clearinghouse and Lending 
Library, and current communication 
conduits such as the Regional Network 
System. 
 10:5 Continue the biannual cooperative 
administration of the Youth Risk 
Behavior Survey (YRBS) with the NH 
Department of Education for data 
collection relative to youth Rx drug 
abuse prevalence, perceived risk, 
availability and perceived 
wrongness and ensure Rx drug 
questions are worded to maximize 
understanding of issue and causes 
Number and nature of 
Rx drug questions on 
YRBS 
 
Number of schools & 
students participating  
 
Data outputs  
 
SFY 2013 & 
ongoing 
This action item relies on shared 
resourcing between the NH Bureau of Drug 
and Alcohol Services (BDAS) and the NH 
Department of Education. Data 
dissemination takes place through schools 
and the Bureau’s Regional Network System 
serving community substance use 
prevention priorities 
10:6 Continue to support the state’s 
annual administration of the 
Behavioral Risk Factor Surveillance 
System (BRFSS) through DHHS Health 
Statistics and Data Management for 
data collection relative to Rx drug 
misuse and abuse 
Annual BRFSS Data 




SFY 2012 & 
ongoing 
In SFY 2009 the Bureau contributed 
leadership and funding to add questions to 
the BRFSS relative to prescription drug 
misuse and abuse to collect data on adult 
prevalence and trends. This action is 
shared with the NH Department of Public 
Health Services. 
 
10:7 Leverage the work of the State 
Epidemiological Outcomes 
Workgroup (SEOW) for increased 
analysis and indicator 
determinations to support the state’s 
ongoing surveillance of prescription 
drug misuse, abuse, & impacts; make 
de-identified prescription data 
available to the SEOW for 
epidemiological  analyses 
SEOW data products SFY 2012 & 
ongoing 
The NH SEOW is making final revisions of 
an epidemiological data profile and  
recommendations for alcohol and drug 
monitoring, including prescription drug 
misuse and abuse. It is due for 





























The New Hampshire Department of Corrections will be responsible for the following objectives in 
service to the state’s commitments to prevent and reduce prescription drug misuse, misdirection 
and abuse among corrections populations re-entering New Hampshire communities.   
It is acknowledged here that the New Hampshire Department of Corrections launched a 
comprehensive, successful “in-house” response to the growing number of inmates who were 
entering correctional facilities with pain and addiction challenges by instituting a pain 
management clinic and new prescribing protocols that ensured inmates accessed a multi-
disciplinary team to treat and manage chronic pain conditions through therapies including physical 
therapy, group therapy, diet and exercise rather than a single modality of just medication.   
 
Between 2008 and 2010, the number of hydrocodone-acetaminophen (Vicodin) pills dispensed per 
month to New Hampshire inmates fell from 18,400 to 2,700.  In addition, for those whose 
medications are managed within correctional facilities, the Department ensures that individuals 
who rely on prescription medication are prescribed those medications that will be accessible 
through Medicaid or other low-cost options, that inmates leaving correctional facilities have a  
14-day supply of needed medications, and that, when possible, inmates leaving facilities are 
connected with a primary care facility.  This strategy ensures that individuals will be able to access 
their prescriptions safely and affordably without having to resort to crime or inappropriate 
diversion for their medical needs. The activities below further reflect their ongoing commitment to 
supporting individuals in their re-entry to communities and traditional community health care and 
mental health care settings.    
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
11:1 Support increased training 
of parole/probation 
officers and applicable 
department of corrections 
staff regarding 
sensitivities of Rx 
medication with this 
population 




SFY 2012 & 
ongoing 
This action requires interagency coordination and 
shared resources to support curriculum development 
and trainers. The action also requires dissemination 
channels and policy adaptation to encourage and/or 
require attendance at trainings. Topics may include 
the myths v. facts of high risk populations, due 
diligence of medical proof of Rx need such as x-rays 
or physical findings, the role of patient contracts, 
and other topics. 
 
SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
11:2 Continue screening and 
assessment of population 
for risk of prescription 
drug abuse upon intake 
and re-entry to community 
Number of screenings 
and assessments  
SFY 2012 & 
ongoing 
With Second Change Act  funding, the department 
has developed Memoranda of Understanding and/or 
contracts with community systems of care to support 
improved care and support as the population re-
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The New Hampshire Department of Education is committed the following objectives in service to 
the state plan to prevent and reduce prescription medication misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
12:1 Increase the number of trainings and 
professional development opportunities 
made available to school personnel relative 
to prevalence and prevention of Rx drug 
misuse and abuse 




SFY 2012 & 
ongoing 
Training opportunities may be 
coordinated with the NH Drug 
Diversion Unit and other  
state-level partners. 
 
PUBLIC EDUCATION & AWARENESS 
 Commitment Action Indicator(s) Time Frame Notes 
12:2 Provide leadership on Rx drug abuse 
through Open Letters to principals and 
school communities noting importance of 
Rx drug awareness and abuse prevention 
Number and dissemination 
of notices relative to Rx 
drug abuse originating 
from the Department 
SFY 2012 & 
ongoing 
Collaboration between the 
Department of Education and the 
Commission’s prevention task 
force can support this. 
12:3 Allow department communication 
channels to be used to disseminate 
information on Rx drug abuse prevention 
best practices, Take-Back events, 
training opportunities, public 
awareness, and related topics 






SFY 2012 & 
ongoing 
This action requires information sources to 
connect to the Department’s communication 
channels, such as NH Drug Diversion Unit 
presentations to school principals, 
Partnership for a Drug Free NH messaging 
and materials to schools, local coalition and 
regional network messaging to school 
personnel and families, etc. 
 
SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
12:4 Continue the biannual  administration of 
the Youth Risk Behavior Survey (YRBS) 
that includes questions relative to Rx 
drug abuse prevalence, perceived risk, 
availability and perceived wrongness; 
ensure Rx drug questions are worded to 
maximize understanding of issue and 
causes 
Number & nature of Rx 
drug questions on 
YRBS 
 
Number of schools & 




SFY 2012 & 
ongoing 
This action item relies on shared 
resourcing between the NH Department 
of Education and the NH Bureau of Drug 
and Alcohol Services. Data 
dissemination takes place through 
schools and the Bureau’s Regional 
Network System serving community 
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 Commitment Action Indicator(s) Time Frame Notes 
12:5 Continue to seek grant 
funding and other 
resources to enhance and 
expand health promotion 
and risk prevention 
specific to Rx drug abuse 
Resources sought and 
acquired 
  
SFY 2013 & 
ongoing 
The federal and state fiscal climate has affected 
resource opportunities such as the closure of  
the federal Safe and Drug Free Schools program), 
while ACA reform may provide more resources 
































The New Hampshire Department of Safety has been a leader in bringing visibility, attention and 
resources to the growing epidemic of prescription drug abuse in New Hampshire within the 
Department, within the Commission, and within the state at large to coordinate an effective 
response to the epidemic.  Specifically, the Department launched a Drug Diversion Unit staffed by 
a state trooper and pharmacist who specialize in drug diversion investigations across the state and 
who commit 50% of their time to training and educating other law enforcement, safety and other 
professionals in prescription drug abuse and diversion.   
 
The New Hampshire Department of Safety is committed the following objectives in service to the 
state plan to prevent and reduce prescription medication misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
13:1 Increase the number of trainings 
and professional development 
opportunities available to and 
accessed by law enforcement and 
other safety personnel (e.g. DWI of 
Rx Drugs, Rx drug forgery) 
Number of training 
curricula developed, 




SFY 2012 & 
ongoing 
This action will be implemented in 
partnership with Policy Standards and 
Training Unit, the Drug Diversion Unit, and 
other stakeholders. Topics may include 
enforcing DWI laws applicable to influence of 
Rx drugs, investigating Rx drug forgery cases, 
investigating “Doctor Shopping”, and other 
relevant topics. 
 
PUBLIC EDUCATION & AWARENESS 
 Commitment Action Indicator(s) Time Frame Notes 
13:2 Develop and disseminate 
Intelligence Bulletins specific to 
Rx drug abuse using the existing 
resources of the Intelligence 




SFY 2012 & 
ongoing 
In cooperation with the Attorney General’s 
office, develop an intelligence bulletin strategy 
specific to the prescription drug threat to 
implement within the law enforcement and 
across multiple stakeholder systems such as 
pharmacies, hospitals, schools, practitioner 
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The New Hampshire Division of Liquor Enforcement is committed the following objectives in 
service to the state plan to prevent and reduce prescription medication misuse, misdirection and 
abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
14:1 Increase the number of 
law enforcement 




Number of law 
enforcement trained in 
ARIDE annually 
SFY 2012 & 
ongoing 
ARIDE training helps officers become more 
proficient at detecting, apprehending, testing, and 
prosecuting impaired drivers and helps prosecutors 
familiarize themselves with drugs that impair 
driving and proper documentation needed to 




14:2 Increase the number of 
law enforcement and other 
personnel trained as Drug 
Recognition Experts (DREs) 
Number of law 
enforcement and other 
personnel trained as 
DREs annually  
 
SFY 2012 & 
ongoing 
Drug Recognition Experts are able to determine if 
an individual is under the influence of a prescription 
drug and may increase the efficacy of law 
enforcement efforts relative to Rx drug abuse. 
 
STORAGE & DISPOSAL  
 Commitment Action Indicator(s) Time Frame Notes 
14:3 Continue to support local Take-
Back events through shared 




Rx Take-Back events and 
outcomes 
 
SFY 2012 & 
ongoing 
The Division of Liquor Enforcement has 
provided support to several communities 
during local Take-Back events and is 
committed to continuing that effort. 
 
New Hampshire Division of Liquor Enforcement 
 





































The New Hampshire Division of Public Health Services is committed to being a responsive, 
expert, leadership organization that promotes optimal health and wellbeing for all.  As the state 
public health department, the Division holds a unique leadership position in the state’s public 
health system, setting direction based on science and the public health needs of our residents and 
serving as the steward for state and federal funds used to deliver essential public health services. 
The Division also holds the authority and accountability to enforce laws to protect the public’s 
health.   
 
The state’s public health department oversees the community health center system, including one 
center that is involved in a national learning collaborative with the U.S. Centers for Medicaid & 
Medicare Services on better integration of patient education, prescribing practices and even an on-
site pharmacy.  Both this system and maternal and child health services are aware of increasing 
prescription drug misuse and abuse among patients and clients and have begun to focus attention 
to the problem. 
 
Through its mission and service array, the Division of Public Health Services is well poised to 
support and promote state-, community-, and provider-level strategies in service to the growing 
problem of prescription drug misuse and abuse and is committed to the following objectives in 
service to the state plan to prevent and reduce prescription medication misuse, misdirection and 
abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
15:1 Support access to and 
availability of training and 
professional development 
relative to evidence-based 
approaches to prevent 
prescription drug misuse 
and abuse  






SFY 2012 & 
ongoing 
This action item will leverage state partner agency 
resources for cross-training opportunities for systems 
of care overseen by the Division.  
These training resources may include those offered by the New 
Hampshire Training Institute on Addictive Disorders, the New 
Hampshire Department of Safety, and the boards of nursing, medicine, 
and pharmacy. Training topics may include patient education, 
prescribing practices, when to refer patients to specialized pain care, 
and problem identification and referral related to abuse or dependence.   
PUBLIC EDUCATION & AWARENESS 
 Commitment Action Indicator(s) Time Frame Notes 
15:2 Support public education and 
awareness activities specific to 
Rx drug abuse through existing 
dissemination channels and 
service delivery systems 
  
Number and 
dissemination of Rx drug 
prevention media and 
other communications
  
SFY 2012 & 
ongoing 
The Division will encourage dissemination of 
existing public education materials within 
public health service systems, including patient 
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SURVEILLANCE & MONITORING 
 Commitment Action Indicator(s) Time Frame Notes 
15:3 Continue to collect and provide access to data 
relative to prescription drug misuse and 
abuse, including the state’s annual 
administration of the Behavioral Risk Factor 
Surveillance System (BRFSS) and 
hospital/emergency room admissions and 
discharges through the Division of Health 
Statistics and Data Management; as PMP data 
become available, work with PMP to support 
periodic epidemiological analyses and reports 
on data trends and implications 
Data collection and 
reporting activity  
SFY 2012 & 
ongoing 
The Division is committed to 
sustaining key data collection and 
monitoring systems to support 
prescription drug abuse 
surveillance and monitoring.  

















The New Hampshire Medical Society plays an active role in the landscape of prescription drug 
abuse prevention through support and leadership relative to legislative policy, professional 
development, standards and guidelines, and information dissemination.  The Medical Society 
maintains a special task force on opioid pain management and provides a comprehensive list of 
resources to support practitioners in effective pain management and abuse deterrence.  The New 
Hampshire Medical Society is committed the following objectives in service to the state plan to 
prevent and reduce prescription medication misuse, misdirection and abuse. 
 
PROFESSIONAL DEVELOPMENT & TRAINING 
Commitment Action Indicator(s) Time Frame Notes 
16:1 Continue to provide access to training 
and professional development 
relative to prescription drug abuse 
and diversion  
Number of trainings 




SFY 2012 & 
ongoing 
This action will leverage the cross-training 
opportunities with other stakeholders, 
including Department of Safety’s Drug 
Diversion Unit and Board of Pharmacy.  
 
PUBLIC EDUCATION & AWARENESS 
 Commitment Action Indicator(s) Time Frame Notes 
16:2 Support legislation relative to 





SFY 2012 & 
ongoing 
The Medical Society is actively engaged in the 
legislative process for current version  
of prescription drug monitoring program and 
supports data access for those prescribers  
not using electronic health records.  
 
16:3 Utilize existing communication 
channels (e.g. list serves, web 
resources) to disseminate emerging 
data, recommendations, guidelines, 
and other information in support of 
effective prescribing practices 
Dissemination data
  
SFY 2012 Disseminated information may include sample 
patient contracts, screening and assessment 
tools, guidelines for referral to addiction 
treatment, referring to specialty pain care, 
prevention of abuse/diversion, patient 
information cards, and other topics. 
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CONTENT OF EDUCATION PROGRAM 
 
The training for prescribers required by the elements to assure safe use must contain the 
following content: 
 
1. General information for safe opioid prescribing 
a. Patient selection and assessment 
i. Determine goal of therapy  
ii. Assessment of the risk of abuse, including history of substance abuse and 
serious mental illness 
iii. When relevant, determining if patient is opioid tolerant 
b. Considerations when prescribing opioids 
i. Pharmacokinetics and potential for overdose 
ii. Addiction, abuse, and misuse 
iii. Intentional abuse by patient or household contacts 
iv. Interactions with other medications/substances 
c. Managing patients taking opioids 
i. Establishing goals for treatment and evaluating pain control 
ii. Use of Patient Provider Agreements (PPAs) 
iii. Adherence to a treatment plan 
iv. Recognizing aberrant behavior 
v. Managing adverse events 
d. Initiating and modifying dosing of opioids for chronic pain 
i. As first opioid 
ii. Converting from one opioid to another 
1. Converting from immediate-release to extended-release and long-
acting products 
2. Converting from one extended-release and long-acting product to 
another 
iii. Titrating to effect/tolerability 
iv. How to deal with missed doses 
e. Maintenance 
i. Reassessment over time 
ii. Tolerance 
f. Monitoring patients for misuse and abuse 
i. Utilization of prescription monitoring programs to identify potential abuse 
ii. Understanding the role of drug testing 
iii. Screening and referral for substance abuse treatment 
g. How to discontinue opioid therapy when it is not needed any longer 
2. Product Specific Information  
a. Pharmacokinetic characteristics 
b. Product specific toxicity 
c. Requirements for opioid tolerance for certain long-acting and extended-release 
products 
d. Individual product information modules 
i. Fentanyl transdermal system 
ii. Hydromorphone ER 
iii. Methadone (For the treatment of moderate to severe pain not responsive to 
non-narcotic analgesics) 
iv. Morphine ER 
v. Oxycodone ER 
vi. Oxymorphone ER 
vii. Buprenorphine (for the management of moderate to severe chronic pain in 
patients requiring a continuous, around-the-clock opioid analgesic for an 
extended period of time) 
viii. New products 
3. Patient counseling 
a. Information about prescribed opioid 
b. How to take opioid properly 
i. Adherence to dosing regimen 
ii. Risk from breaking, chewing, crushing certain products 
c. Reporting adverse effects  
d. Concomitant use of other CNS depressants, alcohol, or illegal drugs 
e. Discontinuation of opioid 
f. Risks associated with sharing, i.e., overdose prevention 
g. Proper storage in the household  
i. Avoiding accidental exposure 
h. Avoiding unsafe exposure by preventing theft and proper disposal 
i. Purpose and content of Patient Provider Agreement 
PATIENT EDUCATION 
Materials to provide to patients as part of patient counseling must include: 
1. How to take opioid properly 
a. Adherence to dosing regimen 
b. Risk from breaking, chewing, crushing certain products 
c. Symptoms of overdose 
2. Reporting adverse effects 
3. Concomitant use of other CNS depressants, alcohol, or illegal drugs 
4. Discontinuation of opioid 
5. Risks associated with sharing 
6. Proper storage in the household  
a. Avoiding accidental exposure 
7. Avoiding unsafe exposure by preventing theft and proper disposal 
8. Purpose and content of Patient Treatment Agreement 




Initial REMS Approval: XX/XXXX 
Most Recent Modification: XX/XXXX 
 
Application number TRADE NAME (DRUG NAME) 





RISK EVALUATION AND MITIGATION STRATEGY (REMS) 
 
I.  GOAL: 
Reduce serious adverse outcomes resulting from inappropriate prescribing, misuse and abuse of 
extended-release (ER) and long-acting (LA) opioids while maintaining patient access to pain 
medications.  Adverse outcomes of concern include addiction, unintentional overdose, and death.  
 
II. REMS ELEMENTS: 
 
 A.  Medication Guide or PPI 
 
A Medication Guide will be dispensed with each [drug name] prescription.  [Describe in detail 
how you will comply with 21 CFR 208.24.] 
 
 B.  Communication Plan 
A communication plan is not required.   
 C.  Elements To Assure Safe Use 
 
1. The sponsor must ensure that training is provided to prescribers who prescribe DRUG.  An 
outline of the content for this information is described in Appendix A.  The training must 
include successful completion of a knowledge assessment and proof of successful program 
completion. To assure access to DRUG and minimize the burden on the healthcare delivery 
system, FDA expects that the training will be conducted by accredited, independent 
continuing medical education (CME) providers, to the extent practicable.  
   
2. The sponsor must provide to prescribers information that the prescriber can use to educate 
patients in the safe use, storage, and disposal of opioids.  An outline of the content for this 
information is described in Appendix B.   
 
3. The sponsor must inform prescribers of the existence of the REMS and the need to 
successfully complete the necessary training. 
 
D. Implementation Plan 
 
An implementation plan is not required. 
 
 E.  Timetable for Submission of Assessments 
 
COMPANY will submit REMS Assessments to the FDA no less frequent than 6 months, 12 
months, and annually after the REMS is initially approved from the date of approval of the 
REMS.  To facilitate inclusion of as much information as possible while allowing reasonable 
time to prepare the submission, the reporting interval covered by each assessment should 
conclude no earlier than 60 days before the submission date for that assessment.  COMPANY 
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AL* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain  
 
Ala. Admin. Code r. 540-X-4-08. 
 
 
AK  Prescribing controlled substances, 
*Alaska Admin. Code tit. 12, § 
40.975.  
*AS 11.71 Controlled Substances 
*AS 08.80.030(11) PMP 
Established AS 17.30.200 
Controlled substance Rx 
Database 
 
*The Use of Controlled Substances for the 
Treatment of Pain by Advanced Nurse 
Practitioners: 
http://www.commerce.state.ak.us/occ/pub/nur18
08.pdf  (Adopted June 2006) 
 
AZ* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Chronic Pain 
(Approved 09/24/97, Revised 
06/03; Spring 2006) 
http://www.azmd.gov/Statutes-
Rules/7_policy.aspx  
*Arizona Revised Statutes 
section 41-1033 
*Ariz. Rev. Stat. Sect. 13-
3412.01 
* A.R.S. Controlled Substances, 
Title 36, Ch 27- Uniform 
Controlled Substances Act 
*A.A.C. Title 4, Ch 23, Article 5- 
Board of Pharmacy- Controlled 
Substances Rules 
 
AZ-O* Guidelines: The Prescribing of 
Controlled Substances for the 






*Advisory Opinion: Use of Controlled 
Substances for the treatment of Pain Management 




Pain%20rev%20Jan09.pdf   
AR* * Regulation 2(6)  
(Effective 03/13/97, Amended 
12/3/98) 
*Chronic Intractable Pain 
Treatment Act, Ark. Code Ann. § 
17-95-701 through 17-95-707. 










CA* * Guidelines for Prescribing 
Controlled Substances for 
Intractable Pain  




* Statement by the Board 
(Issued 07/94) 
 
* Intractable Pain Treatment Act, 
Prescription or administration of 
dangerous drugs or prescription 
controlled substances for 
treatment of pain or condition 
causing pain, Cal. Bus. & Prof. 
Code § 2241.5.  
* Pain Patient’s Bill of Rights, 
Findings and declarations; opiate 
drugs; pain management, Health 
& Safety Code § 124960.  
*Board of Pharmacy: 
http://www.pharmacy.ca.gov/licensing/prescribe_
dispense.shtml  
*Board of Registered Nursing: 
http://www.rn.ca.gov/pdfs/regulations/npr-b-
09.pdf  
*California guidelines resulted from a state 
sponsored summit in which 120 health care 
practitioners, professional and public educators, 
representatives from professional schools and 
associations and health care consumers met to 
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*Uniform Controlled Substances 
Act: Cal. Health & Safety Code, 
Div. 10 Sec 11000 
recommend solutions to legal, professional, and 
educational barriers to effective pain 
management. A report, Summit on Effective Pain 
Management: Removing Impediments to 
Appropriate Prescribing, was issued by the 
Governor of California 
CA-O See CA above   
CO* (1) Guidelines for Prescribing 
Controlled Substances for 
Intractable Pain 
(Adopted 05/16/96) 
(2) Model Policy for the use of 
Controlled Substances for the 

















* Adopted FSMB Model Policy 
*Controlled Substances Act: 
Colo. Rev. Stat. Sect 18-18-308 




CT* Statement on the Use of 
Controlled Substances for the 
Treatment of Pain  







* Adopted FSMB Model Policy *Nursing Board Policy Statement also adopted 
FSMB Model Policy (12/06): 
http://aspi.wisc.edu/documents/pdf/CTnursepolic
y.pdf  
DE* Model Policy for the use of 
Controlled Substances for the 





* Adopted FSMB Model Policy 
*16 Del. C., Ch 47 Sect 4701-
4701-4796 (DE Office of 
Controlled Substances) 






DC Standards for the Use of 
Controlled Substances for the 




f   
D.C. Mun. Regs. tit. 17, § 4614.  *Pharmaceutical Control Division/Health 
Regulation & Licensing Administration 
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FL* * Management of Pain Using 




* Joint Statement on Pain 
Management-Florida Boards of 
Medicine, Nursing, Osteopathic 
Medicine and Pharmacy  
(Approved 09/19/05) 
* Fla. Stat. § 458.326. 
* Pain Management and 
Palliative Care, Fla. Stat. § 
765.1103. 
* Fla. Admin. Code. Ann. r.  




OF PRACTICE FOR MEDICAL 
DOCTORS&ID=64B8-9.013 
(effective 11/28/10) 
*Pain Clinics (effective 10/1/10): 
http://www.doh.state.fl.us/mqa/m
edical/info_SB2272.pdf  (was SB 
2272; SB2722  CH 2010-211) 
 
FL-O* *Standards for the Use of 
Controlled Substances for 
Treatment of Pain  
(Adopted 03/9/00) 
* Joint Statement on Pain 
Management-Florida Boards of 
Medicine, Nursing, Osteopathic 
Medicine and Pharmacy  
(Approved 09/19/05) 
* Fla. Admin. Code. Ann. r. 
64B15-14.005. 
 
GA * Guidelines for the Use of 
Controlled Substances for 
Treatment of Pain: Ten Steps 
(Adopted 01/11/08) 
*GA Ann. Tit. 16, Ch 13 
*GA State Board of Pharmacy 
Rule 480-22 
 
Guam None found   
HI * *Pain Management Guidelines 
(Adopted 01/06, modified 
03/08/06) 
* Adopted FSMB Model Policy 
 
 
ID* *Guidelines: Prescribing 
Opioids for Chronic Pain 
(Effective 03/95) 
* Model Policy for the use of 
Controlled Substances for the 
Treatment of Pain  
(Adopted 08/05) 
* Adopted FSMB Model Policy 
* Uniform Controlled Substances 
Act: Title 37, Ch 27 
 
IL  *Controlled Substances Act: 
Admin. Code Title 77, Ch VI, 
Part 1650 
 
IN  *Title 35 Article 48: Controlled 
Substances 
 
IA* * Standards of practice--
appropriate pain management  
* Joint Statement on Pain by the 
Iowa Boards of Medicine, 
Nursing, Pharmacy and 
Physician Assistants  
 




KS* * Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain 
(Adopted 10/17/98) 
* Adopted FSMB Model Policy 
* Legislative findings on pain 
treatment, Kan. Stat. Ann § 65-
4976. 
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* Joint Policy Statement of the 
Kansas Boards of Healing Arts, 
Nursing and Pharmacy on the 
Use of Controlled Substances 




*Persons suffering from pain; use 
of controlled substances for pain 
treatment, Kan. Stat. Ann § 65-
4977 and 4101 
* K.A.R. 68-20-1 
 
KY* * Model Guidelines for the Use 
of Controlled Substances in Pain 
Treatment 







* Guidelines for Prescribing 
Controlled Substances (Adopted 
06/20/96) 
*KY Controlled Substances Act: 
*KRS 218A; and KRS 217- Food 
Drug and Cosmetic Act 
 
*Operates KY All Schedule Prescription 
Electronic Reporting (KASPER) System 
LA* *Medications used in the 
Treatment of Non-Cancer-
Related Chronic or Intractable 
Pain 






*La. Admin Code. tit. 46, pt. 




ME* *Use of Controlled Substances 
for Treatment of Pain 
(Effective 06/13/2010) 
* Adopted FSMB Model Policy 
(added section on end of life 
pain therapy) 
*Code Me. R 02-373 Ch. 11, § 1 
through 3 
*32 MRSA §3269(3), (7) 
 
 
ME-O* * Use of Controlled Substances 
for Treatment of Pain (Effective 
06/13/2010) 
* Adopted FSMB Model Policy 
(added section on end of life 
pain therapy) 
*Code Me. R 02-383 Ch. 11, § 1 
through 3. 
*32 MRSA §2562 
 
MD* *Guidelines for Prescribing 
Controlled Drugs 
(Adopted 03/96) 
Source: Maryland BPQA 
Newsletter, Vol. 4, num. 1, pp. 1-
3, Mar. 1996 (Similar to FSMB) 
 
MA* * Prescribing Practices, Policy 
and Guidelines 
(Adopted 05/3/89, Amended 
5/19/2010) 
* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain  
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MI* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted in 
2003) 
* Adopted FSMB Model Policy 
*Mich. Comp.Laws Sect 
333.16204a (advisory cmte on 
pain and symptom management) 
*Intractable Pain: Mich. Comp. 
Laws sect 333.16204b-c 
*To develop a booklet on 
intractable pain 333.16204d 
 
 
MI-O* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain  
(Adopted in 2003) 
* Adopted FSMB Model Policy 
 
 
MN* *Endorsed Model Policy for the 
Appropriate Use of Controlled 
Substances for the Treatment of 
Pain 
*Model Guidelines for the Use 
of Controlled Substances for the 
Treatment of Pain (Adopted Fall 
2000) 
* Joint Statement on Pain 
Management (Adopted 09/04) 
*Present a Chronic Pain 







* Adopted FSMB Model Policy 





MS * Use of Controlled Substances 
for Chronic (Non-Terminal) 
Pain (Effective 04/18/99) 
*Pain, Pain Management and 
Mississippi State Board of 
Medical Licensure Scrutiny 
(Effective Fall 1997) 
MSBML Newsletter - Fall 1997 
- Vol.1, No.10 
* Code Miss. Rules 50 013 001. 
Ch. 25 Sec. 6. 
 
 
MO* *Guidelines for the Use of 
Controlled Substances for the 








* Adopted FSMB Model Policy 
* Intractable Pain Treatment 
Act—definitions, Mo. Rev. Stat. 
§ 334.105. 
* Prescription, administration, 
and dispensing controlled 
substances for intractable pain--
therapeutic use--drug 
dependency, Mo. Rev. Stat. § 
334.106. 
*JOINT STATEMENT OF THE MISSOURI 
STATE BOARD OF REGISTRATION FOR 
THE HEALING ARTS AND THE MISSOURI 
BOARD OF PHARMACY ON INTERNET 
PRESCRIBING AND DISPENSING: 
http://pr.mo.gov/boards/healingarts/PharmInterne
tPrescribeDispense.pdf  
MT * Statement on the use of 
Controlled Substances in the 
Treatment of Intractable Pain 
(Adopted 03/15/96) 
*Joint Board Policy Statement 
of the prescribing and filling of 
* Adopted FSMB Model Policy 
(adopted 1/23/09; rev. 3/27/09) 
*MT Medical Assoc. Bulletin, 
Vol. 51, num. 1, March 15, 1996, 
pp3-4 
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controlled substances in the 
treatment of chronic pain 
(Adopted 07/27/02) 
NE* * Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain 
(Effective 02/7/99) 
(2) Model Policy for the use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
06/05) 
* Adopted FSMB Model Policy 
* Ch. 71. Public Health & 
Welfare, Art. 24., (D) Drugs, Pain 
Management, Neb. Rev. Stat. §§ 




NV* * Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain 
(Adopted 07/19/00) NAC 
630.187 
* Model Policy for the Use of 
Controlled Substances for the 
Treatment of Pain 
* Adopted FSMB Model Policy 
* Adoption by reference, Nev. 
Admin. Code ch. 630, s 187. 
* Prescribing or administering 
certain controlled substances for 
treatment of intractable pain not 
grounds for disciplinary action, 
Nev. Rev. Stat. § 630.3066. 
* Exemption from grounds: 
"Intractable pain" defined, Nev. 
Rev. Stat. § 630:255. 
 
NV-O  *NRS 633.521    
NH* * Guidelines for the Use of 
Controlled Substances in the 
Management of Chronic Pain 
(Amended 03/08/09) 
* Adopted FSMB Model Policy 




NJ * Limitations on prescribing, 
administering or dispensing of 
controlled substances; special 
exceptions for management of 
pain  N.J. Admin. Code 13:35-
7.6. 
  
NM* * Guidelines on Prescribing for 
Pain (Effective 04/05/99) 
* Management of Chronic Pain 
with Controlled Substances 
(Effective 01/20/03) 
* Joint Statement on the 
Management of Chronic Pain 
(Adopted 05/2005) 
* Pain Relief Act, N.M. Stat. 
Ann. §§ 24-2D-1 through 24-2D-
6. 





NM-O *Joint Statement on the 
Management of Chronic Pain 
(Adopted 08/2005) 
  
NY *Policy Statement for the Use of 
Controlled Substances for the 





NC* * Management of Chronic Non-
Malignant Pain Statement 
(Adopted 09/13/96) 
*End-Of-Life Responsibilities 
and Palliative Care Statement 
(Adopted 10/21/99) 
* Joint Statement on Pain 
Management and End-Of-Life 
* Adopted FSMB Model Policy 
*North Carolina Board of 
Medical Examiners  
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Care (Adopted 10/21/99) 
* Policy for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
07/05) 
ND *Controlled Substances for Care 
and Treatment (Effective 
08/1/95, Revised 03/14/05) 
*N.D. Cent. Code §§ 19-03.3-01 
through 19-03.3-06. 
*ND Board of Nursing Statement on Pain: 
https://www.ndbon.org//opinions/role%20of%20
nurse%20in%20pain%20mgmt.asp  
NMI None found   
OH *Position Paper-Scheduled Drug 
Therapy Including Narcotics for 
Chronic Benign Pain (Effective 
06/14/95-Revised 08/14/96) 
* Authority to treat intractable 
pain with dangerous drugs, Ohio 
Rev. Code Ann. § 4731.052; 
Continuing medical education 
course on treating intractable 
pain,  Ohio Rev. Code Ann. § 
4731.283 
* Intractable Pain Treatment, 
Ohio Admin. Code §§ 4731-21-
01 to 4731-21-06. 
 
 
OK* * Guidelines for Prescribing 
Controlled Substances for 
Intractable Pain 
(Effective in 1995) 
* Use of Controlled Substances 
for the Treatment of Pain 
(Effective 03/10/05) 
* Adopted FSMB Model Policy 
* Appropriate pain management--
high dosages of controlled 
dangerous drugs, Okla. Stat. tit. 
63, § 2-551.  
* Use of controlled substances for 
the management of chronic pain, 
Okla. Admin. Code § 435:10-7-
11. 
  
OK-O  *OAC 510:5-9-1 Through 5-9-3  
OR * Statement of Philosophy-
Appropriate Prescribing of 
Controlled Substances 
(Adopted 05/20/91) 
* Statement of Philosophy-Pain 
Management in Acute 
Conditions and in Terminal 
Illness (Adopted 04/95) 
* Current Statement of 
Philosophy on Pain 
Management 
(Adopted 04/16/99, Revised 
07/9/04) 
* Pain Treatment Act, Or. Rev. 
Stat. Ann. §§ 677.470 through 
677.480. 
* Written Notice Disclosing the 
Material Risks Associated with 
Prescribed or Administered 
Controlled Substances for the 
Treatment of "Intractable Pain," 
Or. Admin. R §§ 847-015-0030. 
 
*The Pain Management Commission is 
established within the Department of Human 
Services (SB885 2001) 
PA* * Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain (Effective 
10/20/98) State Board of 
Medicine bulletin, Winter 
1998/99, pp. 4-5 
* Adopted FSMB Model Policy 
* Prescribing, administering and 
dispensing controlled substances, 
Pa. Code tit. 49, § 16.92. 
 
PA-O    
PR None found   
RI* * Guidelines for Long Term 
Pain Management 
(Adopted 05/10/95-Referenced 
CA policy) Newsletter of the 
Rhode Island Board of Medical 
* Intractable Pain Treatment, R. I. 
Gen. Laws §§ 5-37.4-1 through 
5-37.4-3. 
*2002, Pain Assessment Act: RI 
Pub Laws 331 
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Licensure and Discipline,  
Summer 1995, p.2 
*Practitioners Immunity from 
disciplinary action for 
prescription for pain management 
RI Pub. Laws 046 
SC* *Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
02/99) 
* Adopted FSMB Model Policy *Joint Position Statement on Pain Management 
for The South Carolina Board of Nursing and 
The South Carolina Board of Pharmacy 
SD* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
01/99) 
* Adopted FSMB Model Policy  
TN* *Management of Prescribing 
with Emphasis on Addictive or 
Dependence Producing Drugs 
Statement (Approved 09/19/95) 
*9 Step Process Similar to NC 
and MN 
* Authority of Physician to 
Prescribe for the Treatment of 
Pain, Tenn. Comp. R. & Regs. 
0880-2-.14(6). 
* Intractable Pain Treatment Act, 
Tenn. Code Ann. §§ 63-6-1101 
through 63-6-1111. (2001 Tenn. 
Pub. Acts 327) 
 
 
TN-O* Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain 




TX* *Pain Control Statement 
(Adopted Spring/Summer 1993) 
Newsletter, Volume 15, num. 1, 
Spring/Summer 1993, p.1 
* Board Rules, Administrative 
Code, Title 22, Part 9, Chapter 
170, Pain Management 
(Effective 01/04/07) 
* Intractable Pain Treatment Act, 
Tex. Occupations Code §§ 
107.001 through 107.201.  
* Pain Management, Tex. Admin. 
Code tit. 22, §§ 170.1 - 170.3. 
* Texas Controlled Substances 
Act, Chapter 481 of the Texas 
Health and Safety Code, relating 
to the prescribing and dispensing 
of controlled substances 
 
*Effective September 1, 2010, a pain 
management clinic may not operate in Texas 
without obtaining a certificate from the Texas 
Medical Board (TMB) 
 
UT* * Guidelines for the Use of 
Controlled Substances for the 
Treatment of Pain (Effective 
02/10/99) 
* Prescribing Controlled 
Substances for Cancer Pain: 
Position Paper (Adopted 
04/10/92) 
* Adopted FSMB Model Policy 
* Unprofessional Conduct, Utah 
Admin. Code r.156-1-502.(6).  
 
* HB 28: active prescribing practitioners are 
required to register with the Controlled Substance 
Database by September 30, 2010 
http://www.commerce.utah.gov/releases/10-10-
26_opl-csd-growth.pdf  
*HB 89 License for Controlled Substances 
Amendments (Rep Morley) 
- modifies the Controlled Substance Precursor 
Act; provides for the Division of Occupational 
and Professional Licensing to issue a controlled 
substance precursor license, which combines the 
current controlled substance precursor purchaser 
and controlled substance distributor licenses.  
 
UT-O See UT above   
VT* *Report of the Prescribing 
Practices Committee (Adopted 
06/05/96) 
* Policy for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
* Adopted FSMB Model Policy  
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VT-O See VT above   
VA* * Guidelines for the Use of 
Opioids in the Management of 
Chronic, Noncancer Pain 
(Adopted 02/05/98) 
* Model Policy for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
06/24/04) 
* Adopted FSMB Model Policy 
*Prescription in excess of 
recommended dosage in certain 
cases, Va. Code Ann. §§ 54.1-




VI None found   
WA * Guidelines for Management of 
Pain (Approved 04/18/96) 
[* Regulation of Manufacture, 
Distribution and Dispensing of 
Controlled Substances, 
Prescriptions, Wash. Rev. Code § 
69-50-308(g). 
* Pain Management, Wash. 
Admin. Code §§ 246-919-800 
through 830.] 
**A new section is added to chapter 18.57A 
RCW 35 to read as follows: 
36 (1) By June 30, 2011, the board shall repeal its 
rules on pain 
37 management, WAC 246-854-120 through 
246-854-150. 
ESHB 2876.PL p. 4 
1 (2) By June 30, 2011, the board shall adopt new 
rules on chronic, 
2 noncancer pain management that contain the 
following elements: 
3 (a)(i) Dosing criteria, including: 
4 (A) A dosage amount that must not be 
exceeded unless an osteopathic 
5 physician's assistant first consults with a 
practitioner specializing 
6 in pain management; and 
7 (B) Exigent or special circumstances under 
which the dosage amount 
8 may be exceeded without consultation with a 
practitioner specializing 
9 in pain management. 
10 (ii) The rules regarding consultation with a 
practitioner 
11 specializing in pain management must, to the 
extent practicable, take 
12 into account: 
13 (A) Circumstances under which repeated 
consultations would not be 
14 necessary or appropriate for a patient 
undergoing a stable, ongoing 
15 course of treatment for pain management; 
16 (B) Minimum training and experience that is 
sufficient to exempt an 
17 osteopathic physician's assistant from the 
specialty consultation 
18 requirement; 
19 (C) Methods for enhancing the availability of 
consultations; 
20 (D) Allowing the efficient use of resources; 
and 
21 (E) Minimizing the burden on practitioners 
and patients. 
22 (b) Guidance on when to seek specialty 
consultation and ways in 
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23 which electronic specialty consultations may 
be sought; 
24 (c) Guidance on tracking clinical progress by 
using assessment 
25 tools focusing on pain interference, physical 
function, and overall 
26 risk for poor outcome; and 
27 (d) Guidance on tracking the use of opioids, 
particularly in the 
28 emergency department. 
29 (3) The board shall consult with the agency 
medical directors' 
30 group, the department of health, the 
University of Washington, and the 
31 largest association of osteopathic physician's 
assistants in the state. 
32 (4) The rules adopted under this section do not 
apply: 
33 (a) To the provision of palliative, hospice, or 
other end-of-life 
34 care; or 
35 (b) To the management of acute pain caused 
by an injury or a 
36 surgical procedure. 
 
WA-O    
WV* * Position Statement on the Use 
of Opioids for the Treatment of 
Chronic Non-Malignant Pain 
(Adopted 07/14/97) 
* Model Policy for the Use of 
Controlled Substances for the 
Treatment of Pain (Adopted 
01/10/05) 
*Rational prescribing practices 
or how to avoid board scrutiny, 
92 West Virginia Medical 
Journal 256 (September/October 
1996) 
*Joint Policy Statement on Pain 
Management at the End of Life 
(Approved 03/12/01) 
* Adopted FSMB Model Policy 
* Management of Intractable 
Pain, W. Va. Code §§ 30-3A-1 
through 30-3A-4. 
 
WV-O* *Model Policy for the Use of 
Controlled Substances for the 
Treatment of Pain  
(Adopted 11/04/04) 
*West Virginia Boards of 
Examiners for Registered 
Nurses, Medicine, Osteopathy, 
and Pharmacy  
Joint Policy Statement on Pain 
Management at the End of Life  
Approved: March 12, 2001  
* Adopted FSMB Model Policy  
WI* * Model Policy for the Use of 
Controlled Substances for the 
Treatment of Pain 
* Adopted FSMB Model Policy 
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WY *Policy  Number 40-01 
adopting Wyoming Health Care 
Licensing Boards’ Uniform 
Policy for the Use of Controlled 
Substances in the Treatment of 
Pain(Issued 02/13/09) 
*35-25-206.  Pain Management 
creating a pain management 
advisory committee (2007) 
 
 
For informational purposes only: This document is not intended as a comprehensive statement of the law on this topic, nor to be relied upon as authoritative. 
Non-cited laws, regulation, and/or policy could impact analysis on a case-by-case or state-by-state basis. All information should be verified independently. 
 
* by the states abbrv. indicates policy same or similar to FSMB policy. 
 Visit http://www.medsch.wisc.edu/painpolicy/index.htm for guidelines and statutes by state on the Pain and 
Policy Studies Group website at the University of Wisconsin 
 Newfoundland Medical Council adopted FSMB Model Guidelines in 2000 
 National Association of State Controlled Substances Authorities endorsed FSMB Model Guidelines 10/29/1999 

















Informed Consent and Controlled Substance Agreement  
A.  Patient Consent  
I, _______________________________________, understand and agree to follow  
    Please print your full name  Date of Birth  
the policies regarding the use of opioids, narcotics, or other controlled 
substances for management of chronic conditions.  I understand that 
______________________________ is under no obligation to prescribe these  
      Provider’s Name  
medications for me.  I also understand that breaking the terms within this 
agreement may lead to its termination and/or my dismissal from treatment.  I have 
tried other medical treatments which have not worked to control my condition.   
I also understand that these medications are not expected to entirely eliminate 
all of my symptoms, but are intended to help me to improve my quality of life.  This 
is a decision that I have made after fully discussing the risks, benefits, as well as 
alternatives to this treatment with my provider.  
B. Risks of Medications  
I understand that treatment of my condition with medications does have risks 
including but not limited to:   
 Physical symptoms -constipation; sleepiness or drowsiness; problems with 
coordination or balance that may make it unsafe to operate dangerous 
equipment or vehicles, agitation, confusion; decreased appetite; problems 
urinating; sexual difficulties.  
 Physical dependence – meaning that abrupt discontinuation of the drug may 
lead to withdrawal symptoms including: runny nose, diarrhea, abdominal 
cramping, “goose flesh,” and/or anxiety.  I understand that this may be 
uncomfortable but not life-threatening and the worse symptoms generally 
resolve within 72 hours.  
 Psychological dependence – meaning it is possible that discontinuation of 
the drug may cause me to miss it or crave it.  
 Known or unknown risk to unborn and nursing children.      
Contraception is highly recommended.     _________(initials)  
C. Your responsibilities and Conditions of the Agreement:  
1. I will inform my Provider of any history of problems with substance abuse, 
illegal drugs, or drug dependence.  
2. I am currently not involved in the sale, illegal possession, diversion or 
transport of controlled substances, nor do I live with or associate with 
individuals who do.  If a weeks medical center provider has reason to believe I 
am diverting my medication(s) covered under this contract, it will be 
immediately reported to the appropriate law enforcement agency. Information 
provided to law enforcement will include my name, date of birth and last 
known address.  
3. I will immediately contact the clinic if any severe depression, thoughts of 
suicide or harming others occurs.  
4. I agree to obtain controlled medications only from my provider.  I will notify 
my provider with 24 hours of any prescriptions for controlled substances 
provided by other providers.  
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5. I will use only_______________________________for filling my prescriptions.  
          Name of Pharmacy  
6. I will not change the amount or the frequency of these medications without 
prior approval of my provider.  
7. I will inform my Provider of any alcohol consumption because it may interact 
with the medications prescribed.  
8. I give permission to my Provider or their agents to communicate with Emergency 
Departments, Pharmacists, Law Enforcement, other providers, dentists or others 
as required to ensure my safety during my treatment with controlled substances.        
9. If recommended by my Provider, I will participate in all health care 
consultations, referrals, evaluations, or alternative treatment modalities to 
include psychiatric evaluation, acupuncturist, physical therapy, occupational 
therapy, or other treatment methods prescribed by my provider. I will keep all 
scheduled appointments and understand that this agreement may be cancelled if I 
miss any appointments with my Provider or any recommended treatments.  
10. I understand and consent to have unannounced blood screen, urine tests, or 
pill counts in order to assess my compliance with my medical regimen and identify 
any other medications or substances that I am taking. If notified, I will have 24 
hours to comply with the request. I am aware there are charges for these 
services, and I will be responsible for them.  
11. I will keep my Provider informed of current contact information including 
phone number and address.   
12. I understand, in general, allowances will not be made for lost, stolen, or 
damaged drugs or prescriptions.  
13. I will not call the clinic requesting refills prior to the date due.  
14. Requests for refills must be made before 12 noon, 72 hours prior to 
expiration of the prescription during normal office hours Monday- Friday  
15. The Emergency Department will not be used  for controlled substance 
medication refills and generally, if presenting to the Emergency Department for 
refills, the request will be denied        
_____(initials)  
 
D. Confirmation and Understanding  
 
1. I understand that, in general, my controlled medications may be discontinued if 
any of the following occur:  
 Provider finds that the medications are not effective  
 I give, sell, or misuse drugs  
 I obtain controlled substances from other sources  
 Test results indicate the improper use of my prescribed medications  
   or the use of illegal drugs  
 I violate any of the terms of this consent agreement.  
 
2. I agree that a copy of this document may be given to my primary care provider, 
Emergency Departments, my pharmacist, or other health care providers involved 
in my treatment.  
 
3. I agree that my Provider or their agents may contact law enforcement if there 
is suspicion of my committing illegal activities but not limited to selling drugs 
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I have read this document and understand it. I consent to the use of medications 
to help control my symptoms, and I understand that my treatment with these 
medications will be carried out in accordance with the condition stated above.  
 
    
 
 Patient’s Signature               Date  
 
      
 
 Witness   Date  
E. Providers Certification  
I certify that the above named patient or responsible individual has received a 
careful explanation of the treatment to be provided including the risks and 
benefits to be expected.  I have disclosed alternative methods of treatment 
that might be appropriate for this patient. I have offered to answer any 
questions by the patient and/or responsible individual regarding this 
treatment.  
 
    
 
 Provider’s Signature               Date  
 
 
PROCEDURE FOR OBTAINING CONTROLLED SUBSTANCE PRESCRIPTIONS  
1) A photo ID shall be presented to the receptionist to verify identity.  
2) If someone other than you will be picking up the prescriptions, that person 
must Present a photo id and sign as indicated in #3 below.  
3) A signature will be obtained when picking up controlled substance 
prescriptions  
4) If there is no photo ID presented, the prescription for controlled 
substances will not be given out under ANY circumstances.  
 
By signing you understand the procedure for obtaining the prescriptions for 
controlled substances.  Compliance is part of your contract.  
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It has come to our attention that you have broken your pain agreement with 
your provider at Weeks Medical Center.   The section of the agreement that 
was broken is:  
 
 Prescriptions for controlled substances not filled at the designated 
pharmacy 
 Prescriptions for controlled substances obtained from multiple providers 
 Prescriptions for controlled substances filled at multiple pharmacies. 
 Recurrent requests to fill controlled substances before they were 
due to be refilled. 
 Failure to follow up as agreed. 
 Failed urine drug screening test. 
 Failed pill count. 
 Failure to take controlled substances as directed as confirmed by a 
negative urine test. 
 Notification by authorities of use, sale, diversion, or transport of illegally 
obtained controlled substances (narcotics or illegal drugs). 
 
Consequently, 
 You will no longer be able to obtain care at Weeks Medical Center 
Physician Offices.  If we are treating you for other medical problems not 
related to pain management, we will continue to provide services for these 
conditions for the next 30 days to give you time to establish care with another 
provider.  Upon notice we will forward your records to your new provider at no 
charge.  No additional narcotics will be prescribed to you.  In the event of an 
emergency, you should seek care at the nearest emergency room.   
 
 Weeks Medical Center providers will not prescribe controlled 
substances to you, but your current PCP is willing to continue to treat you 
for your other healthcare issues.   
 
Your current controlled substance prescription will not be refilled.   If you have 
















Prescription Drug Abuse 
NIDAMED Patient Resources Series 
To download this and other flyers in this series, visit http://www.drugabuse.gov/nidamed. 
What You Need To Know 
Prescription drug abuse is the use of  a 
medication not prescribed for you, in a way 
other than prescribed (for example, taking 
too much), or to get high. 
When abused, prescription drugs can be as 
dangerous as “street” drugs, with similar 
effects on the brain, including the possibility 
of addiction. 
Prescription drug abuse is illegal, even 
though most abusers get them from friends 
and family. 
Almost 2.2 million people 12 and older 
abused prescription opioids, including pain 
relievers, stimulants, and sedatives, for the 
first time in 2009 (similar to marijuana). 
Treatment Options 
Available treatments depend on the type  
of medication being abused. 
For Pain Relievers: Addiction treaments 
include medications combined with 
behavioral therapy. 
For Stimulants: Behavioral therapies can be 
useful; studies are under way to discover 
effective medications. 
For Sedatives: Addicted patients should 
undergo medically supervised detoxification 
combined with behavioral therapy. 
Resources 
NIDA’s Web site (http://www.drugabuse.gov) has information on all aspects of drug abuse, 
such as drug effects on the brain and body, prevention of drug use among young people, latest 
research on addiction treatment, and U.S. trends and statistics. 
NIDA also has a teen Web site devoted to information about prescription drug abuse:  
http://teens.drugabuse.gov/peerx. 
The Substance Abuse and Mental Health Services Administration (SAMHSA) has many reports 
and bulletins available on prescription drug abuse http://oas.samhsa.gov/prescription.htm. 
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Prescription Painkiller 
Overdoses in the US
Deaths from prescription painkillers* have 
reached epidemic levels in the past decade. 
The number of overdose deaths is now greater 
than those of deaths from heroin and cocaine 
combined. A big part of the problem is 
nonmedical use of prescription painkillers—
using drugs without a prescription, or using 
drugs just for the “high” they cause. In 2010, 
about 12 million Americans (age 12 or older) 
reported nonmedical use of prescription 
painkillers in the past year.
Enough prescription painkillers were 
prescribed in 2010 to medicate every 
American adult around-the-clock for a month. 
Although most of these pills were prescribed 
for a medical purpose, many ended up in the 
hands of people who misused or abused them. 
Improving the way prescription painkillers are 
prescribed can reduce the number of people 
who misuse, abuse or overdose from these 
powerful drugs, while making sure patients 
have access to safe, effective treatment.
See page 4
Want to learn more? Visit
Enough prescription painkillers 
were prescribed in 2010 to 
medicate every American adult 
around-the-clock for a month.  
In 2010, 1 in 20 people in the 
US (age 12 or older) reported 
using prescription painkillers 
for nonmedical reasons in 
the past year.  
15,000
Nearly 15,000 people die every 




* “Prescription painkillers” refers to opioid or narcotic pain 
relievers, including drugs such as Vicodin (hydrocodone), 
OxyContin (oxycodone), Opana (oxymorphone), and methadone. 
November 2011
National Center for Injury Prevention and Control 




Overdose deaths from prescription 
painkillers have skyrocketed 
during the past decade.
Prescription painkiller overdoses are a 
public health epidemic.  
 ◊ Prescription painkiller overdoses killed nearly 
15,000 people in the US in 2008. This is more 
than 3 times the 4,000 people killed by these 
drugs in 1999. 
 ◊ In 2010, about 12 million Americans (age 12 or 
older) reported nonmedical use of prescription 
painkillers in the past year.
 ◊ Nearly half a million emergency department 
visits in 2009 were due to people misusing or 
abusing prescription painkillers.  
 ◊ Nonmedical use of prescription painkillers costs 
health insurers up to $72.5 billion annually in 
direct health care costs.  
Certain groups are more likely to abuse or 
overdose on prescription painkillers.
 ◊ Many more men than women die of overdoses 
from prescription painkillers.
 ◊ Middle-aged adults have the highest 
prescription painkiller overdose rates.
 ◊ People in rural counties are about two 
times as likely to overdose on prescription 
painkillers as people in big cities.
 ◊ Whites and American Indian or Alaska 
Natives are more likely to overdose on 
prescription painkillers.
 ◊ About 1 in 10 American Indian or Alaska 
Natives age 12 or older used prescription 
painkillers for nonmedical reasons in the past 
year, compared to 1 in 20 whites and 
1 in 30 blacks.
The supply of prescription painkillers is 
larger than ever.
 ◊ The quantity of prescription painkillers sold 
to pharmacies, hospitals, and doctors’ offices 
was 4 times larger in 2010 than in 1999. 
 ◊ Many states report problems with “pill mills” 
where doctors prescribe large quantities 
of painkillers to people who don’t need 
them medically. Some people also obtain 
prescriptions from multiple prescribers by 
“doctor shopping.”
Some states have a bigger problem with 
prescription painkillers than others.
 ◊ Prescription painkiller sales per person were 
more than 3 times higher in Florida, which 
has the highest rate, than in Illinois, which 
has the lowest. 
 ◊ In 2008/2009, nonmedical use of painkillers 
in the past year ranged from 1 in 12 people 
(age 12 or older) in Oklahoma to 1 in 30 in 
Nebraska.
 ◊ States with higher sales per person and 
more nonmedical use of prescription 
painkillers tend to have more deaths from 
drug overdoses. 
A  West Virginia father, age 26, struggling for years with 
pain and addiction after shattering his elbow in a car crash, 
died from a prescription painkiller one week after telling 
his mother he wanted to go to rehab. In New Hampshire, 
a 20-year-old man overdosed on a prescription painkiller 
bought from a friend, becoming the 9th person that year 
to die from drug overdose in his community of  17,000. 
Stories such as these are all too common.
Real-life stories of the epidemic
3
Rates of prescription painkiller sales, deaths and substance 
abuse treatment admissions (1999-2010)
SOURCE: Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 2010
SOURCE: National Vital Statistics System, 2008
SOURCES: National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System 
(ARCOS) of the Drug Enforcement Administration (DEA), 1999-2010; Treatment Episode Data Set, 1999-2009
Kilograms of prescription
painkillers per 10,000 people










Drug overdose death rates by state per 100,000 people (2008)
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Treatment admissions per 10,000 people
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For more information, please contact  




Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333
Publication date: 11/01/2011
What Can Be Done
The US government is
 ◊ Tracking prescription drug overdose trends to 
better understand the epidemic.
 ◊ Educating health care providers and the public 
about prescription drug abuse and overdose.
 ◊ Developing, evaluating and promoting 
programs and policies shown to prevent and 
treat prescription drug abuse and overdose, 
while making sure patients have access to safe, 
effective pain treatment.  
States can
 ◊ Start or improve prescription drug monitoring 
programs (PDMPs), which are electronic 
databases that track all prescriptions for 
painkillers in the state.
 ◊ Use PDMP, Medicaid, and workers’ 
compensation data to identify improper 
prescribing of painkillers.
 ◊ Set up programs for Medicaid, workers’ 
compensation programs, and state-run health 
plans that identify and address improper 
patient use of painkillers.  
 ◊ Pass, enforce and evaluate pill mill, doctor 
shopping and other laws to reduce prescription 
painkiller abuse. 
 ◊ Encourage professional licensing boards to 
take action against inappropriate prescribing.
 ◊ Increase access to substance abuse treatment.
Individuals can
 ◊ Use prescription painkillers only as directed by 
a health care provider.
 ◊ Make sure they are the only one to use their 
prescription painkillers. Not selling or sharing 
them with others helps prevent misuse and 
abuse.
 ◊ Store prescription painkillers in a secure place 
and dispose of them properly.*
 ◊ Get help for substance abuse problems if 
needed (1-800-662-HELP).
Health insurers can
 ◊ Set up prescription claims review programs to 
identify and address improper prescribing and 
use of painkillers.  
 ◊ Increase coverage for other treatments to 
reduce pain, such as physical therapy, and for 
substance abuse treatment.
Health care providers can 
 ◊ Follow guidelines for responsible painkiller 
prescribing, including
• Screening and monitoring for substance 
abuse and mental health problems. 
• Prescribing painkillers only when other 
treatments have not been effective for pain.
• Prescribing only the quantity of painkillers 
needed based on the expected length 
of pain. 
• Using patient-provider agreements 
combined with urine drug tests for people 
using prescription painkillers long term.
• Talking with patients about safely using, 
storing and disposing of prescription 
painkillers.*
 ◊ Use PDMPs to identify patients who are 
improperly using prescription painkillers. 
CS227796-B
* Information on the proper storage and disposal of medications 





















- by DEA Drug Code Number -
DEA CSA 
SUBSTANCE NUMBER SCH NARC OTHER NAMES 
Codeine preparations - 200 mg/(100 ml or 100 gm) V Y Cosanyl,Robitussin A-C,Cheracol,Cerose,Pediacof 
Difenoxin preparations - 0.5 mg/25 ug AtSO4/du V Y Motofen 
Dihydrocodeine preparations 10 mg/(100 ml or 100 gm) V Y Cophene-S, various others 
Diphenoxylate preparations 2.5 mg/25 ug AtSO4 V Y Lomotil, Logen 
Ethylmorphine preparations 100 mg/(100 ml or 100 gm) V Y 
Opium preparations - 100 mg/(100 ml or 100 gm) V Y Parepectolin, Kapectolin PG, Kaolin Pectin P.G. 
Amphetamine 1100 II N Dexedrine, Adderall, Obetrol 
Methamphetamine 1105 II N Desoxyn, D-desoxyephedrine, ICE, Crank, Speed 
Lisdexamfetamine 1205 II N Vyvanse 
Benzphetamine 1228 III N Didrex, Inapetyl 
Cathine 1230 IV N Constituent of "Khat" plant, (+)-norpseudoephedrine 
Cathinone 1235 I N Constituent of "Khat" plant 
Methcathinone 1237 I N N-Methylcathinone, "cat" 
4-Methyl-N-methylcathinone 1248 I N Mephedrone 
Stimulant compounds previously excepted 1405 III N Mediatric 
N-Ethylamphetamine 1475 I N NEA 
N,N-Dimethylamphetamine 1480 I N 
Pyrovalerone 1485 V N Centroton, Thymergix 
Fenethylline 1503 I N Captagon,amfetyline,ethyltheophylline amphetamine 
Pemoline 1530 IV N Cylert 
Fenproporex 1575 IV N Gacilin, Solvolip 
Mefenorex 1580 IV N Anorexic, Amexate, Doracil, Pondinil 
Aminorex 1585 I N has been sold as methamphetamine 
4-Methylaminorex (cis isomer) 1590 I N U4Euh, McN-422 
Mazindol 1605 IV N Sanorex, Mazanor 
Diethylpropion 1610 IV N Tenuate, Tepanil 
Phendimetrazine 1615 III N Plegine, Prelu-2, Bontril, Melfiat, Statobex 
Phenmetrazine 1631 II N Preludin 
SPA 1635 IV N 1-dimethylamino-1,2-diphenylethane, Lefetamine 
Phentermine 1640 IV N Ionamin, Fastin, Adipex-P, Obe-Nix, Zantryl 
Chlorphentermine 1645 III N Pre-Sate, Lucofen, Apsedon, Desopimon 
Clortermine 1647 III N Voranil 
Dexfenfluramine 1670 IV N Redux 
Controlled Substances - by DEA Drug Code Number
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SUBSTANCE NUMBER SCH NARC OTHER NAMES 
Fenfluramine 1670 IV N Pondimin, Ponderal 
Sibutramine 1675 IV N Meridia 
Modafinil 1680 IV N Provigil 
Methylphenidate 1724 II N Concerta, Ritalin, Methylin 
Pipradrol 1750 IV N Detaril, Stimolag Fortis 
Fencamfamin 1760 IV N Reactivan 
Gamma Hydroxybutyric Acid 2010 I N GHB, gamma hydroxybutyrate, sodium oxybate 
Gamma Hydroxybutyric Acid preparations 2012 III N Xyrem 
Embutramide 2020 III N Tributane 
Aprobarbital 2100 III N Alurate 
Barbituric acid derivative 2100 III N Barbiturates not specifically listed 
Butabarbital (secbutabarbital) 2100 III N Butisol, Butibel 
Butalbital 2100 III N Fiorinal, Butalbital with aspirin 
Butobarbital (butethal) 2100 III N Soneryl (UK) 
Talbutal 2100 III N Lotusate 
Thiamylal 2100 III N Surital 
Thiopental 2100 III N Pentothal 
Vinbarbital 2100 III N Delvinal, vinbarbitone 
Amobarbital 2125 II N Amytal, Tuinal 
Amobarbital & noncontrolled active ingred. 2126 III N 
Amobarbital suppository dosage form 2126 III N 
Fospropofol 2138 IV N Lusedra 
Barbital 2145 IV N Veronal, Plexonal, barbitone 
Methylphenobarbital (mephobarbital) 2250 IV N Mebaral, mephobarbital 
Methohexital 2264 IV N Brevital 
Pentobarbital 2270 II N Nembutal 
Pentobarbital & noncontrolled active ingred. 2271 III N FP-3 
Pentobarbital suppository dosage form 2271 III N WANS 
Phenobarbital 2285 IV N Luminal, Donnatal, Bellergal-S 
Secobarbital 2315 II N Seconal, Tuinal 
Secobarbital & noncontrolled active ingred 2316 III N 
Secobarbital suppository dosage form 2316 III N 
Chloral betaine 2460 IV N Beta Chlor 
Chloral hydrate 2465 IV N Noctec 
Dichloralphenazone 2467 IV N Midrin, dichloralantipyrine 
Chlorhexadol 2510 III N Mechloral, Mecoral, Medodorm, Chloralodol 
Ethchlorvynol 2540 IV N Placidyl 
Controlled Substances - by DEA Drug Code Number
11/15/2011 





SUBSTANCE NUMBER SCH NARC OTHER NAMES 
Ethinamate 2545 IV N Valmid, Valamin 
Glutethimide 2550 II N Doriden, Dorimide 
Methaqualone 2565 I N Quaalude, Parest, Somnafac, Opitimil, Mandrax 
Mecloqualone 2572 I N Nubarene 
Methyprylon 2575 III N Noludar 
Paraldehyde 2585 IV N Paral 
Petrichloral 2591 IV N Pentaerythritol chloral, Periclor 
Sulfondiethylmethane 2600 III N 
Sulfonethylmethane 2605 III N 
Sulfonmethane 2610 III N 
Clonazepam 2737 IV N Klonopin, Clonopin 
Chlordiazepoxide 2744 IV N Librium, Libritabs, Limbitrol, SK-Lygen 
Lacosamide 2746 V N Vimpat 
Bromazepam 2748 IV N Lexotan, Lexatin, Lexotanil 
Camazepam 2749 IV N Albego, Limpidon, Paxor 
Clobazam 2751 IV N Urbadan, Urbanyl 
Clotiazepam 2752 IV N Trecalmo, Rize, Clozan, Veratran 
Cloxazolam 2753 IV N Akton, Lubalix, Olcadil, Sepazon 
Delorazepam 2754 IV N 
Estazolam 2756 IV N ProSom, Domnamid, Eurodin, Nuctalon 
Ethyl loflazepate 2758 IV N 
Fludiazepam 2759 IV N 
Halazepam 2762 IV N Paxipam 
Flunitrazepam 2763 IV N Rohypnol, Narcozep, Darkene, Roipnol 
Prazepam 2764 IV N Centrax 
Diazepam 2765 IV N Valium, Diastat 
Flurazepam 2767 IV N Dalmane 
Clorazepate 2768 IV N Tranxene 
Haloxazolam 2771 IV N 
Ketazolam 2772 IV N Anxon, Loftran, Solatran, Contamex 
Loprazolam 2773 IV N 
Lormetazepam 2774 IV N Noctamid 
Zaleplon 2781 IV N Sonata 
Pregabalin 2782 V N Lyrica 
Zolpidem 2783 IV N Ambien, Ivadal, Stilnoct, Stilnox 
Zopiclone 2784 IV N Lunesta 
Mebutamate 2800 IV N Capla 
Controlled Substances - by DEA Drug Code Number
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SUBSTANCE NUMBER SCH NARC OTHER NAMES 
Meprobamate 2820 IV N Miltown, Equanil, Micrainin, Equagesic, Meprospan 
Nitrazepam 2834 IV N Mogadon 
Oxazepam 2835 IV N Serax, Serenid-D 
Medazepam 2836 IV N Nobrium 
Nimetazepam 2837 IV N Erimin 
Nordiazepam 2838 IV N Nordazepam, Demadar, Madar 
Oxazolam 2839 IV N Serenal, Convertal 
Quazepam 2881 IV N Doral 
Alprazolam 2882 IV N Xanax 
Pinazepam 2883 IV N Domar 
Midazolam 2884 IV N Versed 
Lorazepam 2885 IV N Ativan 
Tetrazepam 2886 IV N Myolastan, Musaril 
Triazolam 2887 IV N Halcion 
Temazepam 2925 IV N Restoril 
13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 
17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha- 4000 III N 
androstane 
17Alpha-methyl-3beta,17beta-dihydroxy-5alpha- 4000 III N 
androstane 
17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 
17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl- 4000 III N 
4-hydroxy-17beta-hydroxyestr-4-en-3-one) 
17Alpha-methyl-delta1-dihydrotestosterone (17beta- 4000 III N 17-Alpha-methyl-1-testosterone 
hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) 
19-Nor-4,9(10)-androstadienedione 4000 III N 
19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4- 4000 III N 
ene; 3alpha,17beta-dihydroxyestr-4-ene) 
19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 
19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5- 4000 III N 
ene; 3alpha,17beta-dihydroxyestr-5-ene) 
19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 
1-Androstenediol (3beta,17beta-dihydroxy-5alpha- 4000 III N 
androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-
androst-1-ene) 
1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 
3Alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 
3Beta,17beta-dihydroxy-5alpha-androstane 4000 III N 
4-Androstenediol (3beta,17beta-dihydroxy-androst-4- 4000 III N 4-AD 
ene) 
4-Androstenedione (androst-4-en-3,17-dione) 4000 III N 
4-Dihydrotestosterone (17beta-hydroxyandrostan-3- 4000 III N Anabolex, Andractim, Pesomax, Stanolone 
one) 
Controlled Substances - by DEA Drug Code Number
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SUBSTANCE NUMBER SCH NARC OTHER NAMES 
4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr-
4-en-3-one) 
4000 III N 
4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4-
en-3-one) 
4000 III N 
5-Androstenediol (3beta,17beta-dihydroxy-androst-5-
ene) 
4000 III N 
5-Androstenedione (androst-5-en-3,17-dione) 4000 III N 
Anabolic steroids 4000 III N "Body Building" drugs 
Androstanedione (5alpha-androstan-3,17-dione) 4000 III N 
Bolasterone (7alpha,17alpha-dimethyl-17beta-
hydroxyandrost-4-en-3-one) 
4000 III N 
Boldenone (17beta-hydroxyandrost-1,4-diene-3-one) 4000 III N Equipoise, Parenabol, Vebonol, dehydrotestosterone 
Boldione 4000 III N 
Calusterone (7beta,17alpha-dimethyl-17beta-
hydroxyandrost-4-en-3-one) 
4000 III N Methosarb 
Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one) 4000 III N Alfa-Trofodermin, Clostene, 4-chlorotestosterone 
Dehydrochloromethyltestosterone (4-chloro-17beta-
hydroxy-17alpha-methylandrost-1,4-dien-3-one) 
4000 III N Oral-Turinabol 
Delta1-dihydrotestosterone (17beta-hydroxy-5alpha-
androst-1-en-3-one) 
4000 III N 1-Testosterone 
Desoxymethyltestosterone 4000 III N 
Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-
androstan-3-one) 
4000 III N Drolban, Masterid, Permastril 
Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene) 4000 III N Maxibolin, Orabolin, Durabolin-O, Duraboral 
Fluoxymesterone (9-fluoro-17alpha-methyl-
11beta,17beta-dihydroxyandrost-4-en-3-one) 
4000 III N Anadroid-F, Halotestin, Ora-Testryl 
Formebolone (2-formyl-17alpha-methyl-
11alpha,17beta-dihydroxyandrost-1,4-dien-3-one) 
4000 III N Esiclene, Hubernol 
Furazabol (17alpha-methyl-17beta-
hydroxyandrostano[2,3-c]-furazan) 
4000 III N Frazalon, Miotolon, Qu Zhi Shu 
Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha-
androstan-3-one) 
4000 III N Assimil, Ermalone, Methybol, Tantarone 
Mesterolone (1alpha-methyl-17beta-hydroxy-5alpha-
androstan-3-one) 
4000 III N Androviron, Proviron, Testiwop 
Methandienone (17alpha-methyl-17beta-
hydroxyandrost-1,4-diene-3-one) 
4000 III N Dianabol, Metabolina, Nerobol, Perbolin 
Methandriol (17alpha-methyl-3beta,17beta-
dihydroxyandrost-5-ene) 
4000 III N Sinesex, Stenediol, Troformone 
Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-
1-en-3-one) 
4000 III N Primobolan, Primobolan Depot, Primobolan S 
Methyldienolone (17alpha-methyl-17beta-hydroxyestr-
4,9(10)-dien-3-one) 
4000 III N 
Methyltestosterone (17alpha-methyl-17beta-
hydroxyandrost-4-en-3-one) 
4000 III N Android, Oreton, Testred, Virilon 
Methyltrienolone (17alpha-methyl-17beta-hydroxyestr-
4,9,11-trien-3-one) 
4000 III N Metribolone 
Mibolerone (7alpha,17alpha-dimethyl-17beta-
hydroxyestr-4-en-3-one) 
4000 III N Cheque, Matenon 
Nandrolone (17beta-hydroxyestr-4-en-3-one) 4000 III N Deca-Durabolin, Durabolin, Durabolin-50 
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Norbolethone (13beta,17alpha-diethyl-17beta- 4000 III N Genabol 
hydroxygon-4-en-3-one) 
Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one 4000 III N Anabol-4-19, Lentabol 
Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4- 4000 III N Nilevar, Pronabol, Solevar 
en-3-one) 
Normethandrolone (17alpha-methyl-17beta- 4000 III N Lutenin, Matronal, Orgasteron 
hydroxyestr-4-en-3-one) 
Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa- 4000 III N Anavar, Lonavar, Oxandrin, Provitar, Vasorome 
5alpha-androstan-3-one) 




4000 III N Anadrol-50, Adroyd, Anapolon, Anasteron, Pardroyd 
Stanozolol (17alpha-methyl-17beta-hydroxy-5alpha- 4000 III N Winstrol, Winstrol-V 
androst-2-eno[3,2-c]-pyrazole) 
Stenbolone (17beta-hydroxy-2-methyl--5alpha-androst- 4000 III N 
1-en-3-one) 
Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta- 4000 III N Teolit, Teslac 
1,4-dien-17-oic acid lactone) 
Testosterone (17beta-hydroxyandrost-4-en-3-one) 4000 III N Android-T, Androlan, Depotest, Delatestryl 
Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta- 4000 III N THG 
hydroxygon-4,9,11-trien-3-one) 
Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one) 4000 III N Finaplix-S, Finajet, Parabolan 
JWH-018 (also known as AM678) 7118 I N 1-Pentyl-3-(1-naphthoyl)indole 
JWH-073 7173 I N 1-Butyl-3-(1-naphthoyl)indole 
JWH-200 7200 I N 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole 
Alpha-ethyltryptamine 7249 I N ET, Trip 
Ibogaine 7260 I N Constituent of "Tabernanthe iboga" plant 
Ketamine 7285 III N Ketaset, Ketalar, Special K, K 
Tiletamine & Zolazepam Combination Product 7295 III N Telazol 
CP-47497 7297 I N 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-
phenol 
CP-47497 C8 Homologue 7298 I N 5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-
phenol 
Lysergic acid 7300 III N LSD precursor 
Lysergic acid amide 7310 III N LSD precursor 
Lysergic acid diethylamide 7315 I N LSD, lysergide 
2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 
Marihuana 7360 I N Cannabis, marijuana 
Dronabinol (synthetic) in sesame oil in soft gelatin 7369 III N Marinol, synthetic THC in sesame oil/soft gelatin as
capsule as approved by FDA approved by FDA 
Tetrahydrocannabinols 7370 I N THC, Delta-8 THC, Delta-9 THC, dronabinol and others 
Parahexyl 7374 I N Synhexyl, 
Nabilone 7379 II N Cesamet 
Mescaline 7381 I N Constituent of "Peyote" cacti 
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3,4,5-Trimethoxyamphetamine 7390 I N TMA 
4-Bromo-2,5-dimethoxyamphetamine 7391 I N DOB, 4-bromo-DMA 
4-Bromo-2,5-dimethoxyphenethylamine 7392 I N 2C-B, Nexus, has been sold as Ecstasy, i.e. MDMA 
4-Methyl-2,5-dimethoxyamphetamine 7395 I N DOM, STP 
2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 
2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 
3,4-Methylenedioxyamphetamine 7400 I N MDA, Love Drug 
5-Methoxy-3,4-methylenedioxyamphetamine 7401 I N MMDA 
N-Hydroxy-3,4-methylenedioxyamphetamine 7402 I N N-hydroxy MDA 
3,4-Methylenedioxy-N-ethylamphetamine 7404 I N N-ethyl MDA, MDE, MDEA 
3,4-Methylenedioxymethamphetamine 7405 I N MDMA, Ecstasy, XTC 
4-Methoxyamphetamine 7411 I N PMA 
Peyote 7415 I N Cactus which contains mescaline 
5-Methoxy-N-N-dimethyltryptamine 7431 I N 5-MeO-DMT 
Alpha-methyltryptamine 7432 I N AMT 
Bufotenine 7433 I N Mappine, N,N-dimethylserotonin 
Diethyltryptamine 7434 I N DET 
Dimethyltryptamine 7435 I N DMT 
Psilocybin 7437 I N Constituent of "Magic mushrooms" 
Psilocyn 7438 I N Psilocin, constituent of "Magic mushrooms" 
5-Methoxy-N,N-diisopropyltryptamine 7439 I N 5-MeO-DIPT 
N-Ethyl-1-phenylcyclohexylamine 7455 I N PCE 
1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 
1-Phenylcyclohexylamine 7460 II N PCP precursor 
1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 
Phencyclidine 7471 II N PCP, Sernylan 
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 
N-Ethyl-3-piperidyl benzilate 7482 I N JB 323 
N-Methyl-3-piperidyl benzilate 7484 I N JB 336 
N-Benzylpiperazine 7493 I N BZP, 1-benzylpiperazine 
3,4-Methylenedioxypyrovalerone 7535 I N MDPV 
3,4-Methylenedioxy-N-methylcathinone 7540 I N Methylone 
4-Anilino-N-phenethyl-4-piperidine (ANPP) 8333 II N ANPP 
Phenylacetone 8501 II N P2P, phenyl-2-propanone, benzyl methyl ketone 
1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 
Alphaprodine 9010 II Y Nisentil 
Anileridine 9020 II Y Leritine 
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Coca Leaves 9040 II Y 
Cocaine 9041 II Y Methyl benzoylecgonine, Crack 
Codeine 9050 II Y Morphine methyl ester, methyl morphine 
Acetyldihydrocodeine 9051 I Y Acetylcodone 
Benzylmorphine 9052 I Y 
Codeine-N-oxide 9053 I Y 
Cyprenorphine 9054 I Y 
Desomorphine 9055 I Y 
Etorphine (except HCl) 9056 I Y 
Etorphine HCl 9059 II Y M 99 
Buprenorphine 9064 III Y Buprenex, Temgesic, Subutex, Suboxone 
Codeine methylbromide 9070 I Y 
Dihydrocodeine 9120 II Y Didrate, Parzone 
Oxycodone 9143 II Y OxyContin, Percocet, Endocet, Roxicodone, Roxicet, 
Dihydromorphine 9145 I Y 
Hydromorphone 9150 II Y Dilaudid, dihydromorphinone 
Difenoxin 1 mg/25 ug AtSO4/du 9167 IV Y Motofen 
Difenoxin 9168 I Y Lyspafen 
Diphenoxylate 9170 II Y 
Benzoylecgonine 9180 II Y Cocaine metabolite 
Ecgonine 9180 II Y Cocaine precursor, in Coca leaves 
Ethylmorphine 9190 II Y Dionin 
Hydrocodone 9193 II Y dihydrocodeinone 
Heroin 9200 I Y Diacetylmorphine, diamorphine 
Levomethorphan 9210 II Y 
Levorphanol 9220 II Y Levo-Dromoran 
Isomethadone 9226 II Y Isoamidone 
Meperidine 9230 II Y Demerol, Mepergan, pethidine 
Meperidine intermediate-A 9232 II Y Meperidine precursor 
Meperidine intermediate-B 9233 II Y Meperidine precursor, normeperidine 
Meperidine intermediate-C 9234 II Y Meperidine precursor 
Metazocine 9240 II Y 
Methadone 9250 II Y Dolophine, Methadose, Amidone 
Methadone intermediate 9254 II Y Methadone precursor 
Metopon 9260 II Y 
Dextropropoxyphene, bulk (non-dosage forms) 9273 II Y Propoxyphene 
Dextropropoxyphene dosage forms 9278 IV Y Darvon, propoxyphene, Darvocet, Propacet 
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Morphine 9300 II Y MS Contin, Roxanol, Oramorph, RMS, MSIR 
Hydromorphinol 9301 I Y 
Methyldesorphine 9302 I Y 
Methyldihydromorphine 9304 I Y 
Morphine methylbromide 9305 I Y 
Morphine methylsulfonate 9306 I Y 
Morphine-N-oxide 9307 I Y 
Myrophine 9308 I Y 
Nicocodeine 9309 I Y 
Nicomorphine 9312 I Y Vilan 
Normorphine 9313 I Y 
Pholcodine 9314 I Y Copholco, Adaphol, Codisol, Lantuss, Pholcolin 
Thebacon 9315 I Y Acetylhydrocodone, Acedicon, Thebacetyl 
Acetorphine 9319 I Y 
Oripavine 9330 II Y 
Thebaine 9333 II Y Precursor of many narcotics 
Dihydroetorphine 9334 II Y DHE 
Drotebanol 9335 I Y Metebanyl, oxymethebanol 
Nalorphine 9400 III Y Nalline 
Opium, raw 9600 II Y Raw opium, gum opium 
Acetylmethadol 9601 I Y Methadyl acetate 
Allylprodine 9602 I Y 
Alphacetylmethadol except levo-alphacetylmethadol 9603 I Y 
Alphameprodine 9604 I Y 
Alphamethadol 9605 I Y 
Benzethidine 9606 I Y 
Betacetylmethadol 9607 I Y 
Betameprodine 9608 I Y 
Betamethadol 9609 I Y 
Opium extracts 9610 II Y 
Betaprodine 9611 I Y 
Clonitazene 9612 I Y 
Dextromoramide 9613 I Y Palfium, Jetrium, Narcolo 
Diampromide 9615 I Y 
Diethylthiambutene 9616 I Y 
Dimenoxadol 9617 I Y 
Dimepheptanol 9618 I Y 
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Dimethylthiambutene 9619 I Y 
Opium fluid extract 9620 II Y 
Dioxaphetyl butyrate 9621 I Y 
Dipipanone 9622 I Y Dipipan, phenylpiperone HCl, Diconal, Wellconal 
Ethylmethylthiambutene 9623 I Y 
Etonitazene 9624 I Y 
Etoxeridine 9625 I Y 
Furethidine 9626 I Y 
Hydroxypethidine 9627 I Y 
Ketobemidone 9628 I Y Cliradon 
Levomoramide 9629 I Y 
Opium tincture 9630 II Y Laudanum 
Levophenacylmorphan 9631 I Y 
Morpheridine 9632 I Y 
Noracymethadol 9633 I Y 
Norlevorphanol 9634 I Y 
Normethadone 9635 I Y Phenyldimazone 
Norpipanone 9636 I Y 
Phenadoxone 9637 I Y 
Phenampromide 9638 I Y 
Opium, powdered 9639 II Y Powdered opium 
Opium, granulated 9640 II Y Granulated opium 
Phenoperidine 9641 I Y Operidine, Lealgin 
Piritramide 9642 I Y Piridolan 
Proheptazine 9643 I Y 
Properidine 9644 I Y 
Racemoramide 9645 I Y 
Trimeperidine 9646 I Y Promedolum 
Phenomorphan 9647 I Y 
Levo-alphacetylmethadol 9648 II Y LAAM, long acting methadone, levomethadyl acetate 
Propiram 9649 I Y Algeril 
Opium poppy 9650 II Y Papaver somniferum 
Poppy Straw 9650 II Y Opium poppy capsules, poppy heads 
Oxymorphone 9652 II Y Numorphan 
1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 
Poppy Straw Concentrate 9670 II Y Concentrate of Poppy Straw, CPS 
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Pentazocine 9709 IV N Talwin, Talwin NX, Talacen, Talwin Compound 
Phenazocine 9715 II Y Narphen, Prinadol 
Butorphanol 9720 IV N Stadol, Stadol NS, Torbugesic, Torbutrol 
Piminodine 9730 II Y 
Racemethorphan 9732 II Y 
Racemorphan 9733 II Y Dromoran 
Alfentanil 9737 II Y Alfenta 
Remifentanil 9739 II Y Ultiva 
Sufentanil 9740 II Y Sufenta 
Carfentanil 9743 II Y Wildnil 
Tilidine 9750 I Y Tilidate, Valoron, Kitadol, Lak, Tilsa 
Tapentadol 9780 II Y 
Bezitramide 9800 II Y Burgodin 
Fentanyl 9801 II Y Duragesic, Oralet, Actiq, Sublimaze, Innovar 
Moramide-intermediate 9802 II Y 
Codeine & isoquinoline alkaloid 90 mg/du 9803 III Y Codeine with papaverine or noscapine 
Codeine combination product 90 mg/du 9804 III Y Empirin,Fiorinal,Tylenol,ASA or APAP w/codeine 
Hydrocodone & isoquinoline alkaloid <15 mg/du 9805 III Y Dihydrocodeinone+papaverine or noscapine 
Hydrocodone combination product <15 mg/du 9806 III Y Lorcet, Lortab,Vicodin, Vicoprofen,Tussionex, Norco 
Dihydrocodeine combination product 90 mg/du 9807 III Y Synalgos-DC, Compal 
Ethylmorphine combination product 15 mg/du 9808 III Y 
Opium combination product 25 mg/du 9809 III Y Paregoric, other combination products 
Morphine combination product/50 mg/(100 ml or 100 9810 III Y 
gm) 
Para-Fluorofentanyl 9812 I Y China White, fentanyl 
3-Methylfentanyl 9813 I Y China White, fentanyl 
Alpha-methylfentanyl 9814 I Y China White, fentanyl 
Acetyl-alpha-methylfentanyl 9815 I Y 
Beta-hydroxyfentanyl 9830 I Y China White, fentanyl 
Beta-hydroxy-3-methylfentanyl 9831 I Y China White, fentanyl 
Alpha-methylthiofentanyl 9832 I Y China White, fentanyl 
3-Methylthiofentanyl 9833 I Y Chine White, fentanyl 
Thiofentanyl 9835 I Y Chine white, fentanyl 
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